WO2008153543A2 - Fluorescent mouse model - Google Patents
Fluorescent mouse model Download PDFInfo
- Publication number
- WO2008153543A2 WO2008153543A2 PCT/US2007/022611 US2007022611W WO2008153543A2 WO 2008153543 A2 WO2008153543 A2 WO 2008153543A2 US 2007022611 W US2007022611 W US 2007022611W WO 2008153543 A2 WO2008153543 A2 WO 2008153543A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- promoter
- gene
- transgenic mouse
- mouse
- specific
- Prior art date
Links
- 238000010172 mouse model Methods 0.000 title description 20
- 238000000034 method Methods 0.000 claims abstract description 62
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 238000001727 in vivo Methods 0.000 claims abstract description 23
- 230000007709 intracellular calcium signaling Effects 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims description 107
- 230000014509 gene expression Effects 0.000 claims description 104
- 238000011830 transgenic mouse model Methods 0.000 claims description 100
- 210000001519 tissue Anatomy 0.000 claims description 81
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 239000004098 Tetracycline Substances 0.000 claims description 57
- 229960002180 tetracycline Drugs 0.000 claims description 57
- 229930101283 tetracycline Natural products 0.000 claims description 57
- 235000019364 tetracycline Nutrition 0.000 claims description 57
- 150000003522 tetracyclines Chemical class 0.000 claims description 57
- 230000001939 inductive effect Effects 0.000 claims description 52
- 108091023040 Transcription factor Proteins 0.000 claims description 32
- 102000040945 Transcription factor Human genes 0.000 claims description 32
- 210000004556 brain Anatomy 0.000 claims description 32
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 29
- 229910001424 calcium ion Inorganic materials 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 210000003625 skull Anatomy 0.000 claims description 19
- 102000057128 Olfactory Marker Human genes 0.000 claims description 17
- 101710166569 Olfactory marker protein Proteins 0.000 claims description 17
- 210000003491 skin Anatomy 0.000 claims description 16
- 239000003623 enhancer Substances 0.000 claims description 15
- 108091006047 fluorescent proteins Proteins 0.000 claims description 15
- 102000034287 fluorescent proteins Human genes 0.000 claims description 15
- 230000001537 neural effect Effects 0.000 claims description 14
- 230000000747 cardiac effect Effects 0.000 claims description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 10
- 229960004373 acetylcholine Drugs 0.000 claims description 10
- 108010085238 Actins Proteins 0.000 claims description 9
- 108010051583 Ventricular Myosins Proteins 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 9
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 102000018614 Uromodulin Human genes 0.000 claims description 7
- 108010027007 Uromodulin Proteins 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 6
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 6
- 108010061861 Uroplakins Proteins 0.000 claims description 6
- 229960003722 doxycycline Drugs 0.000 claims description 6
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 claims description 5
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 5
- 101000629029 Homo sapiens Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 5
- 102000012349 Uroplakins Human genes 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 5
- 102000004899 14-3-3 Proteins Human genes 0.000 claims description 4
- 102100039181 Ankyrin repeat domain-containing protein 1 Human genes 0.000 claims description 4
- 101710122305 Ankyrin repeat domain-containing protein 1 Proteins 0.000 claims description 4
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 102000003888 major urinary proteins Human genes 0.000 claims description 4
- 108090000280 major urinary proteins Proteins 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 230000008786 sensory perception of smell Effects 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- 102100032605 Adhesion G protein-coupled receptor B1 Human genes 0.000 claims description 3
- 101710096306 Adhesion G protein-coupled receptor B1 Proteins 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010078554 Aromatase Proteins 0.000 claims description 3
- 102000014654 Aromatase Human genes 0.000 claims description 3
- 101150056519 CYP19A1 gene Proteins 0.000 claims description 3
- 108700005087 Homeobox Genes Proteins 0.000 claims description 3
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims description 3
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims description 3
- 108010059343 MM Form Creatine Kinase Proteins 0.000 claims description 3
- 108010067385 Myosin Light Chains Proteins 0.000 claims description 3
- 102000016349 Myosin Light Chains Human genes 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims description 3
- 108090001108 Troponin T Proteins 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 101150042523 myod gene Proteins 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 108010042121 probasin Proteins 0.000 claims description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 2
- 101150037123 APOE gene Proteins 0.000 claims description 2
- 101150026842 Anp gene Proteins 0.000 claims description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 2
- 101100216294 Danio rerio apoeb gene Proteins 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims description 2
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims description 2
- 101100120051 Homo sapiens FGF1 gene Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000047918 Myelin Basic Human genes 0.000 claims description 2
- 101710107068 Myelin basic protein Proteins 0.000 claims description 2
- 102100031790 Myelin expression factor 2 Human genes 0.000 claims description 2
- 101710107751 Myelin expression factor 2 Proteins 0.000 claims description 2
- 102000003505 Myosin Human genes 0.000 claims description 2
- 108060008487 Myosin Proteins 0.000 claims description 2
- 241000286209 Phasianidae Species 0.000 claims description 2
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims description 2
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims description 2
- 108010071690 Prealbumin Proteins 0.000 claims description 2
- 102100025803 Progesterone receptor Human genes 0.000 claims description 2
- 108700016466 Raichu-Ras Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102000009190 Transthyretin Human genes 0.000 claims description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims description 2
- 102000018070 Uroplakin Ia Human genes 0.000 claims description 2
- 108010066197 Uroplakin Ia Proteins 0.000 claims description 2
- 102000003848 Uteroglobin Human genes 0.000 claims description 2
- 108090000203 Uteroglobin Proteins 0.000 claims description 2
- 102000011759 adducin Human genes 0.000 claims description 2
- 108010076723 adducin Proteins 0.000 claims description 2
- 108010017361 cryptdin 2 Proteins 0.000 claims description 2
- 102000015694 estrogen receptors Human genes 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 108091022862 fatty acid binding Proteins 0.000 claims description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 230000003551 muscarinic effect Effects 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 210000000107 myocyte Anatomy 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 108090000468 progesterone receptors Proteins 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 238000002165 resonance energy transfer Methods 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 108090000195 villin Proteins 0.000 claims description 2
- 102000048238 Neuregulin-1 Human genes 0.000 claims 2
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims 1
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 claims 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 102000040739 Secretory proteins Human genes 0.000 claims 1
- 108091058545 Secretory proteins Proteins 0.000 claims 1
- 108010017604 Shaw Potassium Channels Proteins 0.000 claims 1
- 102000004536 Shaw Potassium Channels Human genes 0.000 claims 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 claims 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 27
- 239000011575 calcium Substances 0.000 abstract description 27
- 229910052791 calcium Inorganic materials 0.000 abstract description 27
- 230000009261 transgenic effect Effects 0.000 abstract description 20
- 239000000203 mixture Substances 0.000 abstract description 10
- 238000013507 mapping Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 4
- 230000004068 intracellular signaling Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 68
- 108700019146 Transgenes Proteins 0.000 description 38
- 241000699660 Mus musculus Species 0.000 description 28
- 235000019645 odor Nutrition 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 26
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 101150024821 tetO gene Proteins 0.000 description 19
- 210000002569 neuron Anatomy 0.000 description 16
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 14
- 210000000956 olfactory bulb Anatomy 0.000 description 14
- 230000008685 targeting Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 12
- 210000001044 sensory neuron Anatomy 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 230000004913 activation Effects 0.000 description 9
- 229940072049 amyl acetate Drugs 0.000 description 9
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 9
- 230000028956 calcium-mediated signaling Effects 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 108700026220 vif Genes Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000023402 cell communication Effects 0.000 description 5
- 230000009087 cell motility Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 210000001121 vomeronasal organ Anatomy 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 102400000058 Neuregulin-1 Human genes 0.000 description 4
- 101150063378 OMP gene Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 210000001706 olfactory mucosa Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000003741 urothelium Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
- 101150114527 Nkx2-5 gene Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 101150061166 tetR gene Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100025142 Beta-microseminoprotein Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010002947 Connectin Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 102000013534 Troponin C Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 108010020169 beta-microseminoprotein Proteins 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- -1 dHAND Proteins 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000008906 neuronal response Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100024151 Cadherin-16 Human genes 0.000 description 1
- 101710196874 Cadherin-16 Proteins 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 101710177922 Gap junction alpha-5 protein Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 101000919394 Mus musculus Aromatase Proteins 0.000 description 1
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 description 1
- 101001018320 Mus musculus Myelin basic protein Proteins 0.000 description 1
- 101100260568 Mus musculus Thy1 gene Proteins 0.000 description 1
- 102000004364 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
- 101150069872 Slc5a2 gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229910002056 binary alloy Inorganic materials 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940005667 ethyl salicylate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009459 hedgehog signaling Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 101150105254 nkx-2.5 gene Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004991 spatiotemporal regulation Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
Definitions
- the present invention relates to compositions and methods for detecting and/or measuring modulation of genetically encoded sensors, e.g., sensors that detect intracellular calcium signaling.
- Such compositions and methods are useful, e.g., in mapping and examining fluctuations of in vivo molecules, e.g., calcium ions, within and between targeted populations of cells.
- a mouse model is provided that is useful for detecting and/or measuring real-time Ca 2+ signaling in an in vivo environment.
- the human brain contains from 10 to 100 billion neurons, and each has hundreds of connections with neighboring neurons. Making sense of these intricate connections is essential to understanding brain function.
- electrodes have been inserted into the brain or patched on a neuron to record neuronal cell activities. Electrical signals offer high temporal resolution, but cannot provide information for a large number of cells simultaneously. Additionally, the surgical implantation of the electrodes compromises the system and requires monitoring to prevent infection.
- Imaging technology has provided a means to monitor a large population of cells simultaneously. Technologies such as functional MRI, computed tomography (CT), and positron emission tomography (PET) have potential to image brain activity and body function in a noninvasive manner. But, these imaging technologies do not provide the necessary temporal and spatial resolution that is necessary to understand cellular function.
- An alternative method is using optical imaging to image cell activity by recording either the calcium transients or the voltage signals by cells.
- these methods have used organic dyes that alter their optical properties in response to changes in their environment.
- the calcium indicator fluo-4 increases its fluorescence in response to increased calcium concentration inside the cell.
- these chemical indicators With these chemical indicators, cellular responses in a large number of cells can be recorded with relatively high temporal and spatial resolution. But, the loading of these dyes into tissue or live animals has been difficult. In general, these dyes must be applied by bulk-loading techniques, such as injection into the target tissues or invasive surgical manipulations.
- the successful use of these chemical indicators is dependent, in large part, on the successful application of the dyes to the target tissues. The use of chemical indicators is limited further by the lack of cell-type specificity.
- GES Genetically encoded sensors
- FP fluorescent protein
- G-CaMP is an engineered protein that contains a calmodulin domain and a calmodulin binding, myosin light chain, kinase, M13 peptide that flanks the circular permutated EGFP (enhanced green fluorescent protein).
- the binding of calcium to G-CaMP induces conformational changes of the protein and significantly increases its fluorescence when excited at 488 nm.
- An improved variant of G-CaMP is G-CaMP2.
- G-CaMP2 fluoresces approximately 22X brighter than G-CaMP and 6X brighter than G- CaMP1.6 (Tallini, Y. N., et al., 2006).
- G-CaMP2 also exhibits a 4- to 5-fold increase in signal between basal calcium and saturating calcium conditions. While genetically encoded calcium sensors hold great promise for studying calcium signaling in complex organ function, they have not been effectively used in mammals in vivo because of poor intrinsic signal strength, inadequate temperature stability, or perturbing interactions between the sensing molecule and endogenous cellular proteins. Thus, there remains a need for compositions and methods for detecting and measuring, e.g., intracellular signaling in vivo.
- the present invention overcomes these and other limitations, particularly of previously available GES, such as for example, calcium sensors, and provides a transgenic non-human animal, e.g., a transgenic mouse, that may be used to detect and/or measure, e.g., intracellular calcium signaling.
- the invention provides a model that allows combinatorial targeting of specific cell populations using genetic crosses to target, e.g., a fluorescent calcium sensor, with high signal-to-noise ratio, to specific types of cells.
- the compositions and methods of the invention provide, e.g., various means to detect and/or measure, e.g., calcium fluctuations in specific cells through temporal regulation of, e.g., calcium sensor expression.
- one embodiment of the invention is a transgenic mouse comprising a first polynucleotide comprising a GES operably linked to an inducible regulatory element and a second polynucleotide encoding a transactivator of the inducible regulatory element operably linked to a tissue-specific regulatory element, wherein expression of the GES may be detected and/or measured optionally in vivo using a non-invasive technique.
- Another embodiment of the invention is a transgenic mouse comprising a first polynucleotide encoding a fluorescent Ca 2+ indicator operably linked to an inducible regulatory element and a second polynucleotide encoding a tetracycline transactivator operably linked to a tissue-specific regulatory element, wherein expression of the fluorescent Ca 2+ indicator may be detected and/or measured optionally in vivo using a non-invasive technique.
- a further embodiment of the invention is a method for identifying a candidate compound that modulates intracellular calcium signaling. This method comprises providing a candidate compound, providing a transgenic mouse according to the present invention, administering the candidate compound to the transgenic mouse, and evaluating an effect, if any, of the candidate compound on intracellular calcium signaling.
- FIG. 1 shows the expression of G-CaMP2 in HEK293 cells containing both tetO-G-CaMP2 and VP22-tTA plasmids.
- Cells co-transfected with the two plasmids show fluorescence, while cells with only one of the plasmids, or neither, are not fluorescent (Control, FIG. 1A).
- the addition of 10 ⁇ M acetylcholine (ACH) induces a subpopulation of cells to respond with increases in fluorescence (FIG. 1 B).
- Acetylcholine activates G-protein coupled muscarinic acetylcholine receptors and mobilizes intracellular calcium. Arrows point to three of the responsive cells (a, b, and c of both FIG. 1A and 1B).
- FIG. 2 illustrates the respective response profiles of cells a (FIG. 2A), b (FIG. 2B), and c (FIG. 2C), as shown in FIG. 1 , to the addition of 10 ⁇ M acetylcholine over time.
- AFU artificial fluorescence unit
- FIG. 3 is a schematic of the transgenic approach used for the inducible expression of G-CaMP2.
- FIG. 3A illustrates the construct used to target the tetracycline transactivator protein (tTA) to the entire population of sensory neurons.
- the tTA gene (tetR and VP16) was inserted in the 3' untranslated DNA flanking the olfactory marker protein (OMP) gene such that its translation is directed by an internal ribosome entry site (IRES).
- OMP olfactory marker protein
- IVS internal ribosome entry site
- FIG. 3B illustrates the construct encoding the Ca 2+ sensor, G-CaMP2, under the control of the tetracycline promoter (tetO).
- the tetracycline promoter includes multiple tetracycline operon enhancer sequences and a minimal promoter. Because the tetO promoter is only active in the presence of tTA protein (round molecules), G-CaMP2 is only expressed in cells that activate the OMP gene.
- FIG. 4 shows images demonstrating the expression of G-CaMP2 in the main olfactory epithelium of compound transgenic mice bearing an OMP-IRES- tTA allele and a TetO-G-CaMP2 allele.
- Transgenic mice bearing an OMP-IRES-tTA allele were crossed with one of 14 founder transgenic lines of mice bearing a TetO- G-CaMP2 allele.
- the resultant G-CaMP2 expression of Line 1 (FIG. 4A), Line 3 (FIG. 4B), Line 4 (FIG. 4C), Line 8 (FIG. 4D), Line 5, and Line 10 (FIG. 4F) are shown. Bright dots indicate G-CaMP2 expressing neurons.
- FIG. 5 shows the neuronal response to odor stimulation.
- the neuronal response of a line 5 OMP-tTA-G-CaMP2 compound transgenic mouse was imaged through the skull. Background fluorescence was detected before odor stimulation (FIG. 5A).
- the odor of amyl acetate, delivered to the nose of the mouse resulted in activation of G-CaMP2 fluorescence in several glomeruli (FIG. 5B).
- the odor of octanal also resulted in activation of several glomeruli as shown by the G- CaMP2 fluorescence (FIG. 5C).
- FIG. 6 is a graph that demonstrates the quantitative analysis of the response of a compound transgenic mouse to different concentrations of amyl acetate stimulation over time.
- An OMP-tTA-G-CaMP2 compound transgenic mouse from Line 5 was stimulated with different concentrations of amyl acetate and the resultant fluorescence was imaged through the skull. Both the right olfactory bulb (black) and the left olfactory bulb (gray) were similarly stimulated.
- FIG. 7 shows the expression pattern targeted by the OMP promoter.
- FIG. 7A A tissue sample isolated from a mouse expressing the marker tauLacZ gene from the OMP locus. This line marks all the sensory neurons in the olfactory system (FIG. 7A).
- OMP-tTA-G-CaMP2 The targeted expression of G-CaMP2 by the OMP promoter using the tetracycline multi-module system described herein (OMP-tTA-G-CaMP2) is shown to faithfully target G-CaMP2 according to the expression pattern of OMP.
- FIG. 7B demonstrates the targeting of G-CaMP2 to the olfactory bulb (OB), main olfactory epithelium (MOE), and vomeronasal organ (VNO).
- OB olfactory bulb
- MOE main olfactory epithelium
- VNO vomeronasal organ
- FIG. 8 shows the dorsal glomeruli of OMP-tTA-G-CaMP2 mice.
- the expression of G-CaMP2 can be detected at the gross level (FIG. 8A) and the cellular level (FIGS. 8B and 8C).
- FIG. 9 demonstrates activated sensory neurons through the un- thinned skull of OMP-tTA-G-CaMP2 mice in response to different odors. Different sensory neurons are activated by amyl acetate (FIG. 9A), than those activated by butyraldehyde (FIG. 9B), or hexanoic acid (FIG. 9C).
- FIG. 10 shows the sequential activation of glomeruli of OMP-tTA-G-
- FIG. 11 shows the sequential activation of glomeruli of OMP-tTA-G-
- FIG. 12 shows the activation of different glomeruli in response to different odors and concentration of odors.
- Amyl acetate activated one set of glomeruli (FIG. 12A)
- butyraldehyde activated another set of glomeruli (FIG. 12B).
- FIG. 12C shows a concentration of 10 "2"
- FIG. 12D shows a concentration of 10 "1
- FIG. 13 shows the G-CaMP2 sequence (SEQ ID NO:1
- the G-CaMP2 used by the invention includes 6 HIS tags on the N-terminus and is encoded downstream of an inducible promoter and upstream of a SV40 polyA sequence (FIG. 13A and Fig. 13B).
- the inducible promoter contains a minimal CMV promoter (CMV miniP) regulated by 4 TetO sequences (tetO) and is separated from G-CaMP2 with a generic intron (FIG. 13B).
- CMV miniP minimal CMV promoter
- tetO TetO sequences
- the present invention provides compositions and methods to detect and/or measure GES activation caused by, e.g., in vivo calcium (Ca 2+ ) signaling of specific tissues.
- the compositions and methods provided herein overcome the low signal-to-noise ratio and in vivo limitations associated with prior attempts to detect and/or measure, e.g., intracellular Ca 2+ signaling.
- the invention allows combinatorial targeting of specific cell populations using, e.g., a tetracycline-based, inducible, modular transgenic system.
- a transgenic mouse comprising a first polynucleotide comprising a GES operably linked to an inducible regulatory element and a second polynucleotide encoding a transactivator of the inducible regulatory element operably linked to a tissue-specific regulatory element, wherein expression of the GES may be detected and/or measured optionally in vivo using a non-invasive technique.
- the GES may be any polypeptide whose physical properties are altered so as to produce a fluorescent signal in the presence of, e.g., specific ions, metabolites or secondary messengers.
- the GES may be a fluorescence (Forster) resonance energy transfer (FRET)-based sensor or a single fluorescent protein (FP)-based sensor.
- FRET fluorescence resonance energy transfer
- FP single fluorescent protein
- Non-limiting examples of FRET-based sensors that may be used in the present invention include FIP-CBsm, Cameleon-2, Split Cameleon-2, Cameleon- 3, YC2.0, YC4.0, YC2.1 , YC3.1 , YC2.3, YC2.6, YC3.12, YC3.2, YC3.3, YC3.6, YC6.1 , TN-L15, TN-humTnC, TN-XL, Split indicator of cAMP, CGY-DeH , Cygnet-2, cGES-GKIB, CGES-DE2, cGES-DE5, Raichu-Ras, Raichu-Rap1, Raichu-Cdc42, Raichu-Rac1 , Raichu-CRIB, Cdc42-inidicator, Cdc42-GEFs-indicator, Raichu-RhoA, Raichu-RBD, ART, AKAR1 , Srk-indicator
- FRET-based sensors are reviewed in, e.g., Souslova, E.A., and Chudakov, D. M., Genetically Encoded Intracellular Sensors Based on Fluorescent Proteins, Biochemistry (Moscow), 72(7):683-97 (2007).
- Non-limiting examples of single FP-based sensors that may be used in the present invention include Camgaroo-1 , Camgaroo-2, G-CaMP, G-CaMP1.6, G-CaMP2, Cameleon, Troponeon, Flash-Pericam, Split-Pericam, Ratiometric- Pericam, Inverse-Pericam, Case 12, Case 16, Cyan-Sinphos, Green-Sinphos, Yellow-Sinphos, and HyPer.
- Single FP-based sensors are reviewed in, e.g., Souslova, E.A., and Chudakov, D. M., supra.
- the FP-based sensor is a G-CaMP2 indicator. More preferably, the G-CaMP2 indicator is a polypeptide having from about 1 to about 25 His residues at its N-terminus.
- the regulatory elements both inducible and tissue-specific - which are defined in further detail below, include nucleotide sequences that encode promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), mRNA, enhancers, splice junctions, and other elements known in the art, which collectively provide for the replication, transcription, post-transcriptional processing and translation of a coding sequence in a recipient cell. Not all of these regulatory elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell/tissue.
- an “enhancer sequence” is meant a nucleic acid sequence that, when positioned proximate to a promoter, confers increased transcription activity relative to the transcription activity resulting from the promoter in the absence of the enhancer domain. Accordingly, an “enhancer” includes a polynucleotide sequence that enhances transcription of a gene or coding sequence to which it is operably linked. A large number of enhancers, from a variety of different sources are well known in the art. A number of polynucleotides which have promoter sequences (such as the commonly-used CMV promoter) also have enhancer sequences.
- the inducible regulatory element includes at least a polynucleotide sequence selected from a tetracycline- or tetracycline derivative-regulated promoter, a steroid-regulated promoter, and a metal-regulated promoter.
- Non-limiting examples of inducible regulatory elements that may be used in the present invention include polynucleotide sequences that include at least a tetracycline-responsive promoter, a doxycycline-responsive promoter, a minocycline- responsive promoter, a metallothionine-responsive promoter, an ecdysone- responsive promoter, other steroid-responsive promoters, a rapamycin-responsive promoter, an interferon regulated promoter, a progesterone receptor-derived promoter, and an estrogen receptor derived promoter.
- the inducible regulatory element is regulated by a tetracycline transactivator, such as for example a tTA or a rtTA, as disclosed in further detail below.
- the tissue-specific regulatory element targets expression of the GES to a desired tissue and/or cell type.
- the tissue-specific regulatory element may target expression of the GES to, e.g., neural, epithelial, muscular, connective, brain, skin, intestine, pancreas, kidney, lung, stomach, liver, retinal, esophagus, colon, prostate, ovary, bladder, uterus, and bone.
- the tissue-specific regulatory element targets expression of the GES to neural or brain tissue.
- Tissue-specific regulatory elements e.g., promoters
- tissue-specific regulatory elements are well know in the art and may be used in accordance with the present invention so long as the regulatory element is effective to target and express a polynucleotide of interest (which encodes the transactivator) in a selected tissue and/or cell type.
- tissue-specific regulatory elements are set forth below:
- the tissue-specific regulatory element may include a neuronal promoter.
- the tissue-specific regulatory element provides specific expression in the central nervous system (CNS).
- CNS central nervous system
- a neural- specific regulatory element is the mouse Thy1 promoter (Ingraham, H. A., Lawless, G. M., Evans, G. A. (1986) The mouse Thy-1.2 glycoprotein gene: complete sequence and identification of an unusual promoter. J Immunol. 136, 1482-1489).
- a neural-specific regulatory element examples include a BDNF promoter, a NGF promoter, a growth factor promoter, an axon-specific promoter, a dend rite-specific promoter, a brain-specific promoter, and a hippocampal-specific promoter.
- a neuron-specific promoter is a neurofilament promoter (Byrne et al., 1989).
- brain-specific regulatory elements include glial fibrillary acidic protein (GFAP) promoter, Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A., GFAP promoter directs astrocyte-specific expression in transgenic mice.
- GFAP glial fibrillary acidic protein
- Non-limiting examples of muscle-specific regulatory elements include muscle creatine kinase promoter, MoI Cell Biol. 1988 Jul;8(7):2896-909. Identification of upstream and intragenic regulatory elements that confer cell-type- restricted and differentiation-specific expression on the muscle creatine kinase gene. Sternberg EA, Spizz G, Perry WM, Vizard D, Weil T, Olson EN.; portions of Duchenne muscular dystrophy gene promoter, H J Klamut, S B Gangopadhyay, R G Worton and P N Ray, MoI Cell Biol.
- a preferred class of muscle-specific regulatory elements is the cardiac-specific regulatory elements.
- Cardiac-specific promoters include, but are not limited to, promoters from the following genes: an alpha-myosin heavy chain gene, e.g., a ventricular alpha-myosin heavy chain gene, a beta-myosin heavy chain gene, e.g., a ventricular beta-myosin heavy chain gene, a myosin light chain 2v gene, e.g., a ventricular myosin light chain 2 gene, a myosin light chain 2a gene, e.g., a ventricular myosin light chain 2 gene, a cardiomyocyte-restricted cardiac ankyrin repeat protein (CARP) gene, a cardiac alpha-actin gene, a cardiac m2 muscarinic acetylcholine gene, ANP gene, a BNP gene, a cardiac troponin C gene, a cardiac troponin I gene, a cardiac troponin T gene, a cardiac sarcoplasmic reticul
- chamber-specific promoters or enhancers may also be employed, e.g., for atrial-specific expression, the quail slow myosin chain type 3 (MyHC3) or ANP promoter, or the cGATA-6 enhancer, may be employed.
- MyHC3 quail slow myosin chain type 3
- ANP quail slow myosin chain type 3
- cGATA-6 enhancer a promoter for ventricle-specific expression
- the iroquois homeobox gene may be employed.
- ventricular myocyte-specific promoters include a ventricular myosin light chain 2 promoter and a ventricular myosin heavy chain promoter.
- promoters and/or enhancers are promoters and enhancers from the Csx/NKX 2.5 gene, titin gene, alpha-actinin gene, myomesin gene, M protein gene, cardiac troponin T gene, RyR2 gene, Cx40 gene, and Cx43 gene, as well as genes which bind Mef2, dHAND, GATA, CarG, E-box, Csx/NKX 2.5, or TGF-beta, or a combination thereof.
- Tissue-specific enhancers may also be employed.
- a preferred atrial-specific enhancer is the cGATA-6 enhancer. In other embodiments, the enhancer is not tissue-specific.
- Non-limiting examples of regulatory elements directing skin-specific transgene expression include keratin promoters such as a K5 promoter, a K6 promoter, or a K14 promoter, or a fragment thereof. These promoters have been used to generate transgenic mice with skin-specific transgene expression (Cataisson et al., J Immunol 171 :2703-2713 (2003); Shibaki et al., J Invest Dermatol 123:109- 115 (2004); Feith et al., Cancer Res 61 :6073-6081 (2001) Vassar et al., Proc Natl Acad Sci USA 86:1563-1567 (1989)). Additionally, U.S. Pat. No.
- 5,811 ,634 discloses the use of promoter/regulatory sequences of a K1 promoter, a K5 promoter, a K6 promoter and a K10 promoter to direct transgene expression to the cells of the skin in a transgenic non-human mammal.
- Esophagus discloses the use of promoter/regulatory sequences of a K1 promoter, a K5 promoter, a K6 promoter and a K10 promoter to direct transgene expression to the cells of the skin in a transgenic non-human mammal.
- a non-limiting example of a regulatory element directing esophagus- specific transgene expression is an Epstein-Barr virus (EBV) ED-L2 promoter, or a fragment thereof.
- EBV ED-L2 promoter has been used to express a transgene in the cells of the esophagus of transgenic mice (Opitz et al., J Clin Invest 110:61- 769 (2002); Fong et al., Cancer Res 63:4244-4252 (2003)).
- EBV Epstein-Barr virus
- Non-limiting examples of regulatory elements directing liver-specific transgene expression are a major urinary protein (MUP) promoter, or a fragment thereof, an albumin promoter, or a fragment thereof, a transthyretin promoter, or a fragment thereof, an apoE promoter, or a fragment thereof, or a phenylalanine hydroxylase promoter, or a fragment thereof.
- MUP major urinary protein
- Non-limiting examples of regulatory elements directing colon-specific transgene expression are a villin promoter, or a fragment thereof and a fatty acid binding protein promoter (FABP), or a fragment thereof. These promoters have been used to generate transgenic mice with colon-specific transgene expression (Pinto et al., J Biol Chem 274:6476-6482 (1999); Janssen et al., Gastroenterology 123:492- 504 (2002); Sweetser et al., Proc Natl Acad Sci 85:9611-9615 (1988); Cobb et al., Cancer 100:1311-1323 (2004)).
- U.S. Application Publication No. US 2003/0177516 discloses the use of the intestinal FABP promoter region to direct transgene expression to the cells of the gut in a transgenic bird. Prostate
- Non-limiting examples of regulatory elements directing prostate- specific transgene expression are a cryptdin-2 promoter, or a fragment thereof, a prostate-specific antigen (PSA) promoter, or a fragment thereof, a C(3)1 promoter, or a fragment thereof, a prostate secretory protein of 94 amino acids (PSP94) promoter, or a fragment thereof, and a probasin promoter, or a fragment thereof.
- PSA prostate-specific antigen
- C(3)1 promoter or a fragment thereof
- PSP94 prostate secretory protein of 94 amino acids
- 6,136,792 discloses the use of promoter/regulatory sequences of the PSA promoter to direct transgene expression to the cells of the prostate in a transgenic non-human mammal. Additionally, U.S. Pat. Nos. 5,952,488 and 5,907,078 disclose the use of the probasin promoter to drive expression of a transgene specifically in the prostate of transgenic non-human mammals. Ovary
- a non-limiting example of a regulatory element directing ovary- specific transgene expression is the ovarian-specific promoter (OSP-1) or a fragment thereof. This promoter has been used to express a transgene in the cells of the ovaries of transgenic mice (Garson et al., J Soc Gynecol Investig 10:244-250 (2003)). Kidney
- Non-limiting examples of regulatory elements directing kidney- specific transgene expression are the uromodulin promoter, or a fragment thereof, the Tamm-Horsfall protein (THP) promoter, or a fragment thereof, and the type 1 gamma-glutamyl transpeptidase promoter, or a fragment thereof. These promoters have been used to generate transgenic mice with kidney-specific transgene expression (Huang et al., BMC Biotechnol 5:9 (2005); Zhu et al., Am J Physiol Renal Physiol 282:F608-F617 (2002); Terzi et al., J Clin Invest 106:225-234 (2000)).
- THP Tamm-Horsfall protein
- 6,888,047 discloses the use of the uromodulin promoter to direct transgene expression to the cells of the kidneys in a transgenic non-human mammal.
- a kidney-specific promoter is the Ksp-cadherin promoter (Yun Bai, et al., 2002) or the Sglt2 promoter (Rubera I, et al., 2004).
- Non-limiting examples of regulatory elements directing bladder- or urothelium-specific transgene expression are the promoters, or fragments thereof, directing expression of the uroplakin genes.
- the uroplakin Il promoter has been used to engineer transgenic mice with transgene expression specifically in urothelium of the bladder (Cheng Cancer Res 62: 4157-4163 (2002); Lin et al., Proc Natl Acad Sci USA 92:679-683 (1995)).
- U.S. Pat. Nos. 5,824,453 and 6,001 ,646 disclose the use of the uroplakin Il gene promoter to produce transgenic animals expressing a transgene specifically in the cells of the bladder urothelium.
- Pat. No. 6,339,183 discloses transgenic animals in which the urothelium-specific expression of a transgene is directed by a uroplakin Ia promoter, a uroplakin mi promoter, or a urohingin promoter.
- a non-limiting example of a regulatory element directing uterus- specific transgene expression is the uteroglobin promoter, or fragments thereof. This promoter has been used to engineer transgenic mice with transgene expression specifically in the uterus (Gomez Lahoz et al., Gene 117:255-258 (1992); Sandmoller et al., 9:2805-2815 (1994)).
- tissue-specific regulatory elements include, but are not limited to, albumin promoters (liver specific; Pinkert et al., 1987), lymphoid specific promoters (Calame et al., 1988), promoters of T-cell receptors (Winoto et al., 1989) and immunoglobulins (Baneriji et al., 1983; Queen and Baltimore, 1983), intestine-specific promoters (Fabp promoter, Bullard, D. C, et al., 2002), pancreas- specific promoters (Edlunch et al., 1985), or mammary gland-specific promoters (milk whey promoter, U.S. Pat. No. 4,873,316).
- tissue-specific regulatory element includes the OMP promoter.
- a transgenic mouse comprising a first polynucleotide encoding a fluorescent Ca 2+ indicator operably linked to an inducible regulatory element and a second polynucleotide encoding a tetracycline transactivator operably linked to a tissue- specific regulatory element.
- expression of the fluorescent Ca 2+ indicator may be detected and/or measured optionally in vivo using a non-invasive technique.
- the GES e.g., fluorescent Ca 2+ indicator
- the inducible regulatory element comprises a tetracycline promoter and that the tissue specific regulatory element comprises an olfactory marker protein (OMP) promoter.
- OMP olfactory marker protein
- the GES e.g., fluorescent Ca 2+ indicator
- the GES is detected or measured using conventional methods known in the art and/or as disclosed further herein.
- "detected,” “detection,” and the like are intended to mean determining whether the GES, e.g., fluorescent Ca 2+ indicator, has been activated by the presence of, e.g., Ca 2+ .
- "measured,” measuring,” and the like are intended to mean monitoring the level of activation and/or quantitating the level of activation of the GES, e.g., Ca 2+ indicator, and relating that to the concentration of, e.g., Ca 2+ .
- Such detection and/or measuring may be carried out in vivo using invasive or non-invasive procedures.
- invasive procedures include modifying the animal to enhance detection and/or measurement of a signal generated by the GES, e.g., fluorescent Ca 2+ indicator, of the present invention.
- Invasive procedures include, e.g., thinning the skull of the animal, e.g., transgenic mouse, using conventional methods known in the art and disclosed in more detail herein.
- tissue samples from the transgenic animal, e.g., mouse may be manipulated ex vivo, in situ, or in vitro.
- a signal from a GES e.g., a fluorescent Ca 2+ indicator
- a brain slice of a transgenic mouse according to the present invention may be detected and/or measured using conventional methods, including those disclosed herein.
- non-invasive procedures include non-surgical and/or minimally invasive procedures for positioning, detecting, and/or measuring a signal generated by a GES, e.g. a fluorescent Ca 2+ indicator, of the present invention.
- Another embodiment of the invention is a method for identifying a candidate compound that modulates intracellular calcium signaling. This method comprises providing a candidate compound, providing a transgenic mouse according to the present invention, administering the candidate compound to the transgenic mouse, and evaluating an effect, if any, of the candidate compound on intracellular calcium signaling.
- “modulates,” “modulation,” and the like means either an increase or decrease in intracellular calcium signaling compared to a transgenic mouse treated with a control.
- “candidate compound” is to be broadly interpreted and includes a biological and/or non- biological agent.
- the candidate compound may be a nucleic acid, polypeptide, polysaccharide, or small organic or inorganic molecule.
- Candidate compounds may include a fusion protein, an antibody, antibody mimetic, domain antibody, targeted aptamer, RNAi, siRNA, shRNA, or an antisense sequence.
- the candidate compound may be administered to the transgenic mouse in any convenient manner.
- the candidate compound may be administered to the transgenic mouse orally, parenterally, sublingually, transdermal ⁇ , rectally, transmucosally, topically, via olfaction, via buccal administration, or combinations thereof.
- Parenteral administration may be intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, or intraarticular.
- the candidate compound is administered to the transgenic mouse through olfaction.
- administration through olfaction means that the candidate compound is presented to the transgenic mouse in such a manner that the candidate compound is inhaled.
- the candidate compound may be administered to the transgenic mouse by delivering it directly to a tissue sample.
- a tissue sample For example, a brain slice from a transgenic mouse according to the present invention may be bathed in a solution containing the candidate compound.
- Other analogous methods well known in the art may be used as well.
- evaluating an effect, if any, of the candidate compound on intracellular calcium signaling means determining whether the candidate compound increased, decreased, or had no effect on intracellular calcium signaling in a specific tissue, such as, e.g., the olfactory bulb (OB), main olfactory epithelium (MOE), or vomeronasal organ (VNO).
- a specific tissue such as, e.g., the olfactory bulb (OB), main olfactory epithelium (MOE), or vomeronasal organ (VNO).
- OB olfactory bulb
- MOE main olfactory epithelium
- VNO vomeronasal organ
- the evaluation step may be carried out in vivo, through a tissue of the transgenic mouse in a non-invasive procedure as disclosed previously.
- the non-invasive procedure is carried out through the skull of the transgenic mouse without thinning or otherwise decreasing the thickness of the skull.
- the evaluation step may be carried out in vivo through a tissue of the transgenic mouse in a more invasive procedure by, e.g., thinning or otherwise decreasing the thickness of the skull.
- Procedures for thinning the skull of a mouse are known in the art and further disclosed in the Examples below.
- the thickness of the skull at a particular site is decreased by, e.g. shaving the skull as disclosed herein, to a thickness less than about 150 ⁇ m, preferably less about than 100 ⁇ m, more preferably less than about 75 ⁇ m, such as for example between about 40-60 ⁇ m, including 50 ⁇ m.
- the evaluating step may also be carried out on tissue obtained from the brain of a transgenic mouse according to the present invention.
- the evaluating step may be carried out on a brain slice.
- the present invention will now be described with reference to a preferred embodiment that exemplifies a tetracycline-based inducible system.
- the tetracycline (tet) inducible system uses regulatory elements from the Tn70-encoded tetracycline resistance operon from E. coli that can be regulated by tet.
- the tetracycline inducible system utilized by the invention includes two components: 1) a transactivator protein (tTA) to regulate gene expression and 2) an inducible regulatory element containing multiple tetracycline resistance operon (tetO) sequences placed upstream of a gene of interest.
- tTA transactivator protein
- tetO multiple tetracycline resistance operon
- the tetracycline transactivator protein is a chimeric protein that consists of a fusion between the herpes simplex virus-transactivating domain VP16 and the tetracycline repressor from E. coli.
- the function of a tTA is to be sensitive to tetracycline and tetracycline derivatives. Such derivatives include doxycycline and minocycline. In the absence of tet or a derivative, tTA binds to the tetO sequences upstream of the gene of interest and activates transcription.
- tet or a derivative In the presence of tet or a derivative, a conformational change in the tetracycline repressor prevents the binding of tTA to tetO and prevents transcription.
- This system has been used both in vitro and in vivo (Fruh et al. 1994; Wimmel et al. 1994; Furth et al. 1994; and Kistner et al. 1996, all incorporated herein by reference).
- rtTA reverse transactivator
- rtTA which binds a tetO sequence in the presence of tet, may also be used in place of tTA.
- the transactivator used depends upon the intended use of the invention.
- the two components of the tet inducible system may be provided in two separate modules.
- the term "module”, as used herein, refers to a subject having within its genome one component, or construct, that is part of a multi- component, or construct, system.
- One module provides the transactivator protein targeted to specific tissues of an organism (e.g., OMP-tTA line), and the other module provides the fluorescent Ca 2+ indicator G-CaMP2 under the control of a tetracycline inducible promoter (G-CaMP2 line).
- G-CaMP2 line tetracycline inducible promoter
- the modules may be any subject, organism, or animal having a central nervous system. Suitable modules include: mammals, humans, mice, rats, dogs, cats, cattle, swine, sheep, and ungulates; preferably the modules are mice or rats; and more preferably the modules are mice.
- the first module of the present invention is exemplified by a tetracycline inducible system, which includes a transgenic mouse that harbors a GES, e.g., a fluorescent Ca 2+ indicator protein (FCIP), encoded downstream of a tet inducible promoter containing tetO sequences.
- a GES e.g., a fluorescent Ca 2+ indicator protein (FCIP)
- FCIP fluorescent Ca 2+ indicator protein
- G-CaMP2 provided by J. Nakai, Laboratory for Memory and Learning, Saitama, Japan
- the resulting nucleic acid was used to generate a transgenic mouse line by introducing the transgene- encoding nucleic acid sequence into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection, or other suitable techniques).
- the oocyte was placed in a pseudo-pregnant female foster animal and allowed to develop into a viable animal.
- Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice have become conventional in the art and are disclosed, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191 ; and Hogan, 1986.
- the TetO-G-CaMP2 transgenic mouse may be crossed with any mouse targeting the activating tTA to a specific tissue in order to evaluate calcium fluctuations and responses in the desired target tissue.
- the TetO-G-CaMP2 transgenic mouse may be crossed with a mouse targeting tTA to the skin to study calcium fluctuations of keratinocytes as they differentiate or with a mouse targeting tTA to motor neurons to study their communication.
- the FCIP encoded by the transgene is G-CaMP2, which is a variant of G-Camp.
- G-CaMP2 contains several mutations and alterations that enhance folding, stability, and fluorescence at physiological temperatures compared to Camp. Nevertheless, expression of G-CaMP2 in vivo has been varied. For example, modest success was achieved in mouse heart muscle by combining surgical exposure of the heart with monitoring G-CaMP2 expression (Tallini, Y. N., et al., 2006). Invasive surgery or sacrifice was required to monitor expression.
- G-CaMP2 was used to study calcium signaling in cerebellar parallel fibers of the mouse brain (Diez-Garcia, J., et al., 2005). Temporal control of expression was not achieved in the Diez-Garcia brain model and monitoring could only be achieved in vitro.
- the present invention overcomes the deficiencies of the previous models by achieving much greater intensity of expression such that G-CaMP2 expression can be advantageously monitored in vivo without animal sacrifice or invasive, life-threatening, surgical procedures (see, e.g., FIGS. 9 and 10).
- the robust expression of the present invention is, in part, due to the particular regulatory element and overall configuration used to create the construct used.
- a skilled artisan will recognize the difficulty associated with generating mice that express, e.g., a Ca 2+ sensor at a level to detect the sensor through an opaque tissue such as the bone. Neither the heart model (Tallini, Y.
- the invention provides high expression capable of real-time detection that is a vast improvement over other models described in the art.
- the G- CaMP2 transgenic mouse of the invention not only can be temporally controlled, but it may also be combined with interchangeable transgenic mice targeting a tetracycline transactivator (tTA or rtTA) to a specific tissue or population of cells to produce compound transgenic mice in which Ca 2+ signaling may be studied in a multitude of targeted tissues or cells.
- tTA or rtTA tetracycline transactivator
- the high expression may be the result of using a CMV minimal promoter regulated by 4 tetO sequences to drive G-CaMP2 expression, the addition of 6 HIS tags to the N-terminus of G-CaMP2, or the combination of the two (see, FIG. 13A and 13B).
- a CMV minimal promoter regulated by 4 tetO sequences to drive G-CaMP2 expression
- the addition of 6 HIS tags to the N-terminus of G-CaMP2
- FIG. 13A and 13B the combination of the two
- At least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, or even 25 HIS tags, or respectively tetO sequences may be useful to either increase or decrease expression such that it is measurable above background autofluorescence.
- a different minimal promoter regulated by the tetO sequences may also be used to alter the expression level achieved by the invention.
- a suitable promoter includes any ubiquitous promoter such as, but not limited to ubiquitinase, ⁇ -actin, GAPDH, ⁇ -kinesin, ROSA, and phosphoglycerate kinase promoters.
- a skilled artisan will also recognize that a combination of alterations may result in an overall change in expression level and the expression level desired depends upon the intended use of the invention.
- the second module of the tetracycline inducible system is a transgenic mouse that expresses the tTA protein in a specific tissue or population of cells.
- tissue-specific regulatory elements that may be used with the invention include those identified above.
- the tTA gene (tetR and VP16) was inserted in the 3' untranslated DNA sequence flanking the OMP gene, such that its translation was directed by an internal ribosome entry site (IRES) (FIG. 3A).
- IRS internal ribosome entry site
- FIG. 3A Cells that activate OMP gene transcription, express a bicistronic RNA encoding both OMP and tTA as described in Yu et al. 2004.
- the tTA protein can be targeted to any specific tissue by encoding it downstream of any tissue- specific regulatory element. It may also be advantageous to target the tissue ubiquitously using an ubiquitous regulatory element, particularly if a temporally-related event, such as development or reproduction, is being evaluated.
- tissue-specific regulatory element could be any regulatory element known in the art and is not limited to tissue-specific or ubiquitous regulatory elements, but also may include engineered regulatory elements.
- the present invention provides a method to generate a "compound" transgenic mouse that expresses G-CaMP2 in a targeted tissue or population of cells.
- the invention does not extend to compound transgenic mice made or known by others or to methods or compositions using them.
- the compound transgenic mouse line encodes both the G-CaMP2 downstream of an inducible regulatory element and a transactivator downstream of a tissue-specific regulatory element.
- Exemplary inducible and tissue-specific regulatory elements provided herein are different from each other; however, depending upon the objectives to be achieved, the two promoters may be the same or variants of each other.
- the first module of the invention a transgenic mouse encoding G-CaMP2 downstream of an inducible regulatory element
- the second module of the invention a transgenic mouse encoding a transactivator downstream of a tissue-specific regulatory element.
- the modules are combined by breeding or crossing the two mouse lines.
- a TetO-G-CaMP2 transgenic mouse (tet-G2) may be crossed to an OMP-IRES-tTA transgenic mouse to generate an OMP-tTA-G-CaMP2 compound transgenic mouse.
- the resultant compound offspring may be identified through Polymerase Chain Reaction (PCR) or Southern blot screening of genomic DNA as known in the art (see, Metzger et a/., 2002).
- mice may be generated by, e.g., mating
- mice containing both tet-G2 and OIVT alleles were used to generate 300 embryos in a week.
- the resulting embryos have both tet-G2 (in 50% of the embryos) and OIVT (in 100% of the embryos).
- These tet-G2 mice have been deposited under the terms of the Budapest Treaty as disclosed in more detail below.
- Transgene expression and expression patterns may be screened using methods such as protein analysis by Western blot; RNA analysis by Northern blot or quantitative RT-PCR, histological analysis, or other methods commonly practiced in the art.
- transgene leakage may be determined by treating (for tTA) or not treating (for rtTA) compound transgenic mice with a tetracycline derivative prior to screening for transgene expression.
- compound transgenic mice using the tTA transactivator may be treated for about 1-3 weeks with about 0.1 , 0.5, 0.75, 1 , 1.5, 2, 5, 7, or 10 mg/mL of doxycycline added to drinking water.
- An increase in transgene expression in the presence of doxycycline indicates transgene leakage. Lines that show a high level of expression with little or no leakage are preferred. Fluorescence Intensity
- An advantage to the present invention is the production of very bright fluorescence by the selected GES, e.g., G-CaMP2, in response to stimuli that allows detection and/or measurement, e.g., in vivo without invasive surgical procedures or implants.
- fluorescence in Line 5 mice is easily visible through the skull to the naked eye.
- animals of the present invention can be used without life-threatening trauma or high risk of infection.
- the subject transgenic mouse upon stimulation, shows substantially greater fluorescence intensity, or brightness, in a cell with an increase of calcium influx/eflux compared to a reference cell without an increase in calcium influx/eflux.
- a sensory neuron of an OMP-tTA-G-CaMP2 compound transgenic mouse will exhibit an increase in fluorescence intensity upon stimulation compared to a non-stimulated neuron.
- the increase in fluorescence intensity upon stimulation is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% (or two- fold), at least about 150%, at least about 2X, 3X, 4X, 5X, 1OX, 15X, 20X 1 25X, 30X 1 40X, 50X 1 75X 1 100X 1 or more, brighter in a stimulated cell compared to a non- stimulated reference cell.
- Brightness may be detected and/or measured using techniques including, but not limited to, visual screening, spectrophotometry, spectrofluorometry, fluorescent microscopy, and fluorescence activated cell sorting (FACS).
- FACS fluorescence activated cell sorting
- the transgenic animals e.g., mice
- the transgenic animals can be used to trace neuronal circuitry. Understanding the pattern of interconnections of specific neural cells is essential to understanding their roles in nervous system function and dysfunction.
- the connections a neuron makes have been identified using electrophysiological recordings, from histochemical techniques or through the use of anterograde or retrograde tracers that make it possible to visualize the patterns of projections of individual neurons. While these approaches have been useful to identify certain aspects of neural connectivity, their invasiveness, unavoidable confounding artifacts, limitation of resolution in space and time, and the inability to reproduce findings with great fidelity limit their utility.
- the transgenic mice e.g., OMP-tTA-G-CaMP2
- the mapping of neuronal circuits can be achieved by a stimulation that results in intracellular calcium fluctuations.
- Neural activity, following stimulation, can be monitored through fluorescence imaging and facilitates the mapping of functional neuronal circuits in the complex environment of the brain.
- OMP-tTA-G-CaMP2 transgenic mice can be stimulated with an odor, such as acetylcholine, ethyl salicylate, 2-butanone, butyraldehyde, hexyl alcohol, butyric acid, hexonoic acid, or limonene.
- the odor can be presented locally in the olfactory bulb to induce the fluorescence of the G-CaMP2 sensor.
- the level of fluorescence intensity can be analyzed through fluorescent imaging of sectioned brain tissue or through the full thickness of the skull.
- the animals can be anesthetized and their skulls thinned to allow in vivo tracing of neuronal projections with fluorescent microscopy.
- calcium signaling can be traced in other tissues by interchanging the OMP-tTA line used to generate the OMP-tTA-G- CaMP2 compound transgenic line with another specific tissue targeting tTA mouse line.
- a transgenic mouse line targeting tTA expression to the skin using a skin specific promoter may be crossed to the TetO-G-CaMP2 line to generate a skin specific G-CaMP2 compound mouse in which calcium signaling in the skin can be traced.
- Other tissues in which it will be desirable to trace calcium signaling include the kidney, muscle, intestine, and those in which cell motility, communication, or signaling is of interest.
- the invention can be used to measure calcium signaling, cell communication, and cell motility in models of pathological disease or subjects having such disease.
- models of disease e.g. mouse models, that are used to study the disease process, study mechanics of the disease, and to test or screen potential therapies, including identification of candidate compounds for modulating such diseases and underlying physiological conditions as disclosed above.
- diseases models include, but are not limited to, mouse models of airway hyper-responsiveness (De Sanctis et al. 1995), alcohol and morphine preference (Berretini et al. 1994; Crabbe et al. 1994), atherosclerosis (Hyman et al.
- the invention may also be used in models using other organisms having a central nervous system such as cats, dogs, rats, guinea pigs, and ungulates.
- a skilled artisan will recognize that many models of human disease are available including, but not limited to, those of Alzheimer's disease, Parkinson's disease, many types of cancer, retinal degeneration, inflammatory bowel disease, diabetes, autoimmunity, atherosclerosis, hypertension, and many more.
- the transgenic mouse of the invention may be used in combination with any mouse model of human disease to study, e.g., the role calcium plays in that disease.
- the TetO-G-CaMP2 transgenic mouse may be crossed to any transgenic mouse encoding a tetracycline transactivator protein (tTA or rtTA) targeted to a specific tissue or ubiquitously expressed.
- tTA or rtTA tetracycline transactivator protein
- the resultant compound transgenic mouse encoding both the transactivator protein and the inducible G-CaMP2, may then be crossed to the desired mouse model of human disease.
- tissue-targeted or ubiquitously expressed transactivator protein depends upon the disease being studied as well as the intended use of the invention.
- the mouse model of human disease provides the study of polycystic kidney disease, then it may be advantageous to target the expression of G-CaMP2 to the kidney or to the specific cell of the kidney affected by polycystic kidney disease. But, if the mouse model of human disease provides the study of cancer affecting multiple tissues, then it may be advantageous to ubiquitously express G-CaMP2.
- MHD-G-CaMP2 inducible G-CaMP2
- MHD-G-CaMP2 inducible G-CaMP2
- Methods to study the M H D-G-CaM P2 mouse model include those disclosed herein and others known in the art. A skilled artisan will recognize that the methods used to study the MHD- G-CaMP2 mouse model depend upon the disease, targeted tissue, and the intended use of the invention. Development
- the invention can be used to study, e.g., calcium signaling, signal transduction, cell communication, and cell motility in development and aging models.
- models may include, but are not limited to, those that over express, inhibit, eliminate, or otherwise alter the expression (tissue-targeted or ubiquitous) of developmental regulators such as those involved in WNT signaling, Hedgehog signaling, BMP signaling, and other signaling pathways or apoptosis.
- the invention may be used in models using a variety of organisms having a central nervous system such as mice, cats, dogs, rats, guinea pigs, and ungulates.
- a preferred model is a mouse.
- the transgenic mouse of the invention may be used in combination with any mouse model to study the role of, e.g., calcium in the developmental or aging process.
- the TetO-G-CaMP2 transgenic mouse may be crossed to any transgenic mouse encoding a tetracycline transactivator protein (tTA or rtTA) targeted to a specific tissue or ubiquitously expressed.
- tTA or rtTA tetracycline transactivator protein
- the resultant compound transgenic mouse encoding both the transactivator protein and the inducible G- CaMP2, may then be crossed to the desired mouse model (MM-G-CaMP2).
- MM-G-CaMP2 desired mouse model
- G-CaMP2 tissue-targeted or ubiquitously expressed transactivator protein depends upon the disease being studied as well as the intended use of the invention. For example, if the mouse model provides loss of function or over expression of a protein in only the skin, then it may be advantageous to target the expression of G-CaMP2 to the skin or a specific cell of the skin. But, if the mouse model provides the loss of function or over expression of a protein in multiple tissues, then it may be advantageous to ubiquitously express G-CaMP2. [0089] Once a mouse model has been crossed to also express an inducible mouse model (MM-G-CaMP2).
- GES such as G-CaMP2 (MM-G-CaMP2)
- G-CaMP2 MM-G-CaMP2
- MM-G-CaMP2 mouse model examples include those described herein and others known in the art.
- a skilled artisan will recognize that the methods used to study the MM-G-CaMP2 mouse model depend upon the disease, targeted tissue, and the intended use of the invention. For example, to study the development process, mice must be time-mated to allow embryos at different stages throughout development to be studied. Methods for studying mouse development are known in the art (see, Kaufman, M.
- mice must be allowed to age and analyzed at various stages during the aging process. Methods for studying mouse aging are known in the art (see, Hasty P. et al., 2003).
- a "fluorescent Ca 2+ indicator” or “FCIP” is a fusion protein based on the fusion of a fluorescent protein with a Ca 2+ sensitive protein. The binding of Ca 2+ to the Ca 2+ sensitive protein results in a conformational change of the fusion protein that in turn results in fluorescence.
- the Ca 2+ sensitivity of the fluorescence readout of FCIPs is generally achieved either via changes in the efficiency of fluorescence resonance energy transfer between two spectral variants of fluorescent proteins or via changes in the pKa of circularly permuted spectral variants of fluorescent proteins.
- a "transgenic mouse” is a mouse, in which one or more of the cells of the animal include a transgene.
- a "transgene” is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.
- Subject means a living being having a central nervous system. Suitable subjects include: mammals, humans, mice, rats, dogs, cats, cattle, swine, sheep, and ungulates.
- An "inducible system” refers to the components necessary to allow temporally controlled expression of a gene of interest. Typically, an inducible system includes an "inducible promoter” that is engineered to contain binding sites for specific substrates not present endogenously. For example, the tetracycline-based inducible system is based on regulatory elements from the Tn70-encoded tetracycline resistance operon from E.
- coli that can be regulated by tetracycline or derivatives of tetracycline.
- the tetracycline inducible system uses a tetracycline transactivator protein (tTA), tetracycline resistance operon nucleic acid sequences from E. coli (tetO), and tetracycline or a derivative thereof.
- tTA tetracycline transactivator protein
- tetO tetracycline resistance operon nucleic acid sequences from E. coli
- tetO tetracycline resistance operon nucleic acid sequences from E. coli
- tetracycline or a derivative thereof tetracycline transactivator protein
- the tTA protein binds to tetO sequences placed upstream of a gene of interest to activate transcription.
- the tTA protein is unable to bind to tetO sequences and transcription is prevented.
- a "tetracycline transactivator” is a protein that has the ability to bind to tetracycline resistance operon (tetO) sequences to activate transcription and is tetracycline sensitive.
- tissue-specific regulatory element means that a given polynucleotide sequence, e.g. a promoter, is transcriptionally active (i.e., directs, the expression of linked sequences sufficient to permit detection of the polypeptide product of the promoter) in less than all cells or tissues of an organism.
- a tissue-specific regulatory element which may include a promoter, is preferably active in only one cell type, but may, for example, be active in a particular class or lineage of cell types (e.g., hematopoietic cells).
- a tissue-specific regulatory element useful according to the invention comprises those sequences necessary and sufficient for the expression of an operably linked nucleic acid sequence in a manner or pattern that is essentially the same as the manner or pattern of expression of the gene linked to that promoter in nature.
- any tissue-specific transcriptional regulatory element known in the art may be used with the invention. Such regulatory elements may be used alone (i.e., a promoter only) or in combination with other regulatory elements.
- ubiquitous regulatory element refers to any regulatory element, including a promoter, natural or engineered, that displays strong activity in a wide range of cells, tissues and cell cycles.
- ubiquitous promoters include, but are not limited to, ubiquitinase, CMV, ⁇ -actin, GAPDH, ⁇ -kinesin, ROSA, and phosphoglycerate kinase promoters.
- operably linked refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other.
- a regulatory element such as a promoter
- Coding sequences can be operably linked to regulatory elements in a sense or antisense orientation.
- the complementary RNA regions of the invention can be operably linked, either directly or indirectly, 5' to the target mRNA, or 3' to the target mRNA, or within the target mRNA, or a first complementary region is 5' and its complement is 3' to the target mRNA.
- operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.
- the term "population of cells” refers to one or more cells arising from at least one stem cell. This includes intact tissue, fractionated/homogenized tissue, cells derived from a tissue, and stem cell cultures isolated from a tissue. [0101]
- the term "expression”, as used herein, refers to the production of a functional end product.
- module refers to a subject having within its genome one component, or construct, that is part of a multi-component, or construct, system.
- a module can be a transgenic animal, such as a “transgenic mouse” having at least one construct inserted into its genome.
- the tetracycline inducible system is a binary system that depends upon two constructs: one encoding a transactivator protein, and one encoding a gene of interest downstream of an inducible promoter containing tetO sequences.
- the two constructs, or modules work together to produce inducible regulation of the expression of the gene of interest.
- Each module can be used interchangeably with other modules that provide either the transactivator protein targeted to one of many modules.
- G-CaMP2 is thermally stable and retains brightness at 37°C. These properties of G-CaMP2 were analyzed in vitro using a mammalian expression
- HEK human embryonic kidney cells
- G-CaMP2 The properties of G-CaMP2 make it an ideal GES to use to monitor calcium fluctuations in vivo in multiple cell types.
- G-CaMP2 was combined with an inducible system with independent targeting potential.
- the tetracycline inducible system provides tissue-specific targeting separate from the gene of interest, so multiple cell types may be targeted by only changing one component of the system instead of both components.
- the gene of interest component of the tetracycline inducible system was generated by placing the expression of the G-CaMP2 sensor under the control of the tetracycline promoter (TetO-G-CaMP2) using standard genetic engineering methods (FIG. 3B).
- the G-CaMP2 used by the invention includes a N-terminal HIS tag of 6 HIS residues (FIG. 13A and 13B).
- the tetracycline promoter contains a minimal CMV promoter regulated by 4 tetO sequences (FIG. 13A and 13B). Transcription of the resulting construct is active in the presence of tTA; therefore, the functionality of the construct was tested in the presence and absence of tTA in a mammalian expression system.
- TetO-G-CaMP2 and a construct containing a tetracycline transactivator protein under the control of a ubiquitous promoter (CMV-VP22-tTA).
- CMV-VP22-tTA ubiquitous promoter
- the cells were incubated at 37°C for 48 hours and approximately 40% of the transfected cell population exhibited fluorescence when excited at 488 nm (FIG. 1A).
- FOG. 1B When this population of cells was challenged with 10 ⁇ M acetylcholine to activate G-protein coupled muscarinic acetylcholine receptors to mobilize intracellular calcium, a subset of cells responded with a robust increase in fluorescence (FIG. 1 B, arrows A, B, and C). The increase
- a TetO-G-CaMP2 mouse was generated by linearizing the TetO-G-
- 14 founder mice carrying the transgene were identified by PCR of tail extracted DNA. The 14 founder mice were crossed to a mouse from the
- OMP-IRES-tTA line (FIG. 3A), which expresses tTA from the OMP allele, targeting it
- G-CaMP2 expressed G-CaMP2 in the olfactory epithelium or the vomeronasal organ.
- FIG. 4B Line 4 (FIG. 4C), Line 5 (FIG. 4E), Line 8 (FIG. 4D), and Line 10 (FIG. 4F)
- the high expression levels allow expression to be detected at the gross level (FIG.
- transgenic mice containing the G-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe (G) mice) containing the G-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- CaMP2 indicator targeted to the olfactory neurons may be used to evaluate neuron stimulation and map the signals sent in the brain.
- the response of sensory neurons was analyzed by stimulating transgenic mice with odor of varying concentrations. After anesthetizing mice with an injection of ketamine, the skin over the olfactory bulb was removed and the underlying skull covering the olfactory bulb was surgically thinned. The mice were then secured on an imaging plate and placed underneath a fluorescent microscope for imaging analysis. Background fluorescence was detected before odor stimulation (FIG. 5A). The odor of amyl acetate, delivered to the nose of the mouse, resulted in several glomeruli activating G-CaMP2 fluorescence (FIG. 5B).
- OMP-tTA-G-CaMP2 mice were presented with three different odors that resulted in three different subsets of neurons becoming activated. Amyl acetate activated different neurons (FIG. 9A and 12A) than those activated by butyraldehyde (FIG. 9B and 12B) or hexanoic acid (FIG. 9C). When OMP-tTA-G-CaMP2 mice were presented with the combination of amyl acetate and butyraldehyde odors different
- the hair over the head is shaved with a razor blade and a midline
- incision is made in the skin covering the skull to expose the olfactory bulb.
- a head holder is glued to the bone and the animal is mounted to the
- microscope stage with the olfactory bulb region positioned right under the lens.
- puffs are used to cool the thinning surface to prevent heat damage of the brain
- Tet-G2 transgenic embryos of the invention were deposited with the
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to compositions and methods useful for detecting and/or measuring, e.g., intracellular signaling in vivo. More particularly, compositions and methods are provided, which include transgenic animals, that are useful in mapping and examining, e.g., calcium fluctuations in vivo between and within populations of cells in real time. Methods for screening for candidate compounds that effect, e.g., intracellular calcium signaling are also provided.
Description
FLUORESCENT MOUSE MODEL
RELATED APPLICATION
[0001] This application relates to and claims priority to U.S. Provisional
Patent Application No. 60/863,301 , which was filed October 27, 2006 and is incorporated herein by reference in its entirety.
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] The invention was made with government support under grant number R01 DC8003 awarded by the National Institute of Deafness and other Communication Diseases (NIDCD). The government may have certain rights in the invention.
FIELD OF THE INVENTION
[0003] The present invention relates to compositions and methods for detecting and/or measuring modulation of genetically encoded sensors, e.g., sensors that detect intracellular calcium signaling. Such compositions and methods are useful, e.g., in mapping and examining fluctuations of in vivo molecules, e.g., calcium ions, within and between targeted populations of cells. Specifically, a mouse model is provided that is useful for detecting and/or measuring real-time Ca2+ signaling in an in vivo environment.
BACKGROUND OF INVENTION
[0004] The human brain contains from 10 to 100 billion neurons, and each has hundreds of connections with neighboring neurons. Making sense of these
intricate connections is essential to understanding brain function. Traditionally, electrodes have been inserted into the brain or patched on a neuron to record neuronal cell activities. Electrical signals offer high temporal resolution, but cannot provide information for a large number of cells simultaneously. Additionally, the surgical implantation of the electrodes compromises the system and requires monitoring to prevent infection.
[0005] Imaging technology has provided a means to monitor a large population of cells simultaneously. Technologies such as functional MRI, computed tomography (CT), and positron emission tomography (PET) have potential to image brain activity and body function in a noninvasive manner. But, these imaging technologies do not provide the necessary temporal and spatial resolution that is necessary to understand cellular function.
[0006] An alternative method is using optical imaging to image cell activity by recording either the calcium transients or the voltage signals by cells. Traditionally, these methods have used organic dyes that alter their optical properties in response to changes in their environment. For example, the calcium indicator fluo-4 increases its fluorescence in response to increased calcium concentration inside the cell. With these chemical indicators, cellular responses in a large number of cells can be recorded with relatively high temporal and spatial resolution. But, the loading of these dyes into tissue or live animals has been difficult. In general, these dyes must be applied by bulk-loading techniques, such as injection into the target tissues or invasive surgical manipulations. The successful use of these chemical indicators is dependent, in large part, on the successful
application of the dyes to the target tissues. The use of chemical indicators is limited further by the lack of cell-type specificity.
[0007] Genetically encoded sensors (GES) have provided a means to monitor cell activity with high temporal and spatial resolution in a noninvasive manner and allow long-term studies of neuronal activity and morphology. Several fluorescent protein (FP) based indicators are available that monitor changes in calcium concentration, synaptic transmission, voltage activation, and kinase activity. Among them, the most widely used indicator belongs to the category of calcium sensors. Such calcium sensors include cameleon, Camgaroo, Troponeon, and G- CaMP (G-CaMP 1.3 and G-CaMP 1.6). G-CaMP is an engineered protein that contains a calmodulin domain and a calmodulin binding, myosin light chain, kinase, M13 peptide that flanks the circular permutated EGFP (enhanced green fluorescent protein). The binding of calcium to G-CaMP induces conformational changes of the protein and significantly increases its fluorescence when excited at 488 nm. An improved variant of G-CaMP is G-CaMP2. At physiological temperatures, G-CaMP2 fluoresces approximately 22X brighter than G-CaMP and 6X brighter than G- CaMP1.6 (Tallini, Y. N., et al., 2006). G-CaMP2 also exhibits a 4- to 5-fold increase in signal between basal calcium and saturating calcium conditions. While genetically encoded calcium sensors hold great promise for studying calcium signaling in complex organ function, they have not been effectively used in mammals in vivo because of poor intrinsic signal strength, inadequate temperature stability, or perturbing interactions between the sensing molecule and endogenous cellular proteins. Thus, there remains a need for compositions and methods for detecting and measuring, e.g., intracellular signaling in vivo.
SUMMARY OF INVENTION
[0008] The present invention overcomes these and other limitations, particularly of previously available GES, such as for example, calcium sensors, and provides a transgenic non-human animal, e.g., a transgenic mouse, that may be used to detect and/or measure, e.g., intracellular calcium signaling. Specifically, the invention provides a model that allows combinatorial targeting of specific cell populations using genetic crosses to target, e.g., a fluorescent calcium sensor, with high signal-to-noise ratio, to specific types of cells. The compositions and methods of the invention provide, e.g., various means to detect and/or measure, e.g., calcium fluctuations in specific cells through temporal regulation of, e.g., calcium sensor expression.
[0009] Thus, one embodiment of the invention is a transgenic mouse comprising a first polynucleotide comprising a GES operably linked to an inducible regulatory element and a second polynucleotide encoding a transactivator of the inducible regulatory element operably linked to a tissue-specific regulatory element, wherein expression of the GES may be detected and/or measured optionally in vivo using a non-invasive technique.
[0010] Another embodiment of the invention is a transgenic mouse comprising a first polynucleotide encoding a fluorescent Ca2+ indicator operably linked to an inducible regulatory element and a second polynucleotide encoding a tetracycline transactivator operably linked to a tissue-specific regulatory element, wherein expression of the fluorescent Ca2+ indicator may be detected and/or measured optionally in vivo using a non-invasive technique.
[0011] A further embodiment of the invention is a method for identifying a candidate compound that modulates intracellular calcium signaling. This method comprises providing a candidate compound, providing a transgenic mouse according to the present invention, administering the candidate compound to the transgenic mouse, and evaluating an effect, if any, of the candidate compound on intracellular calcium signaling.
BRIEF DESCRIPTION OF DRAWINGS
[0012] FIG. 1 shows the expression of G-CaMP2 in HEK293 cells containing both tetO-G-CaMP2 and VP22-tTA plasmids. Cells co-transfected with the two plasmids show fluorescence, while cells with only one of the plasmids, or neither, are not fluorescent (Control, FIG. 1A). The addition of 10 μM acetylcholine (ACH) induces a subpopulation of cells to respond with increases in fluorescence (FIG. 1 B). Acetylcholine activates G-protein coupled muscarinic acetylcholine receptors and mobilizes intracellular calcium. Arrows point to three of the responsive cells (a, b, and c of both FIG. 1A and 1B).
[0013] FIG. 2 illustrates the respective response profiles of cells a (FIG. 2A), b (FIG. 2B), and c (FIG. 2C), as shown in FIG. 1 , to the addition of 10 μM acetylcholine over time. (AFU: artificial fluorescence unit).
[0014] FIG. 3 is a schematic of the transgenic approach used for the inducible expression of G-CaMP2. FIG. 3A illustrates the construct used to target the tetracycline transactivator protein (tTA) to the entire population of sensory neurons. The tTA gene (tetR and VP16) was inserted in the 3' untranslated DNA flanking the olfactory marker protein (OMP) gene such that its translation is directed
by an internal ribosome entry site (IRES). Cells that activate OMP gene transcription and harbor the construct will express a bicistronic RNA encoding both OMP and tTA. In the presence of the tetracycline derivative doxycycline (dox), a conformational change in the Tet repressor (tetR) prevents the binding of tTA to tetO. FIG. 3B illustrates the construct encoding the Ca2+ sensor, G-CaMP2, under the control of the tetracycline promoter (tetO). The tetracycline promoter includes multiple tetracycline operon enhancer sequences and a minimal promoter. Because the tetO promoter is only active in the presence of tTA protein (round molecules), G-CaMP2 is only expressed in cells that activate the OMP gene.
[0015] FIG. 4 shows images demonstrating the expression of G-CaMP2 in the main olfactory epithelium of compound transgenic mice bearing an OMP-IRES- tTA allele and a TetO-G-CaMP2 allele. Transgenic mice bearing an OMP-IRES-tTA allele were crossed with one of 14 founder transgenic lines of mice bearing a TetO- G-CaMP2 allele. The resultant G-CaMP2 expression of Line 1 (FIG. 4A), Line 3 (FIG. 4B), Line 4 (FIG. 4C), Line 8 (FIG. 4D), Line 5, and Line 10 (FIG. 4F) are shown. Bright dots indicate G-CaMP2 expressing neurons.
[0016] FIG. 5 shows the neuronal response to odor stimulation. The neuronal response of a line 5 OMP-tTA-G-CaMP2 compound transgenic mouse was imaged through the skull. Background fluorescence was detected before odor stimulation (FIG. 5A). The odor of amyl acetate, delivered to the nose of the mouse, resulted in activation of G-CaMP2 fluorescence in several glomeruli (FIG. 5B). The odor of octanal also resulted in activation of several glomeruli as shown by the G- CaMP2 fluorescence (FIG. 5C).
[0017] FIG. 6 is a graph that demonstrates the quantitative analysis of the response of a compound transgenic mouse to different concentrations of amyl acetate stimulation over time. An OMP-tTA-G-CaMP2 compound transgenic mouse from Line 5 was stimulated with different concentrations of amyl acetate and the resultant fluorescence was imaged through the skull. Both the right olfactory bulb (black) and the left olfactory bulb (gray) were similarly stimulated. [0018] FIG. 7 shows the expression pattern targeted by the OMP promoter.
A tissue sample isolated from a mouse expressing the marker tauLacZ gene from the OMP locus. This line marks all the sensory neurons in the olfactory system (FIG. 7A). The targeted expression of G-CaMP2 by the OMP promoter using the tetracycline multi-module system described herein (OMP-tTA-G-CaMP2) is shown to faithfully target G-CaMP2 according to the expression pattern of OMP. FIG. 7B demonstrates the targeting of G-CaMP2 to the olfactory bulb (OB), main olfactory epithelium (MOE), and vomeronasal organ (VNO).
[0019] FIG. 8 shows the dorsal glomeruli of OMP-tTA-G-CaMP2 mice. The expression of G-CaMP2 can be detected at the gross level (FIG. 8A) and the cellular level (FIGS. 8B and 8C).
[0020] FIG. 9 demonstrates activated sensory neurons through the un- thinned skull of OMP-tTA-G-CaMP2 mice in response to different odors. Different sensory neurons are activated by amyl acetate (FIG. 9A), than those activated by butyraldehyde (FIG. 9B), or hexanoic acid (FIG. 9C).
[0021] FIG. 10 shows the sequential activation of glomeruli of OMP-tTA-G-
CaMP2 mice by the odor of octanal through the un-thinned skull. Initially, only two glomeruli are activated (FIG. 1OA and 10B). Over time, more glomeruli become
activated as the initially activated glomeruli become less activated (FIG. 1OC and 1OD). The fluorescence intensity of glomeruli a, b, c, d, and e fluctuates over the course of odor exposure (FIG. 10E).
[0022] FIG. 11 shows the sequential activation of glomeruli of OMP-tTA-G-
CaMP2 mice by the odor of butyraldehyde. Initially, few glomeruli are activated (FIG. 11A). Over time, more glomeruli become activated (FIG. 11B, 11C, and 11D). The fluorescence intensity of glomeruli a, b, c, d, e, f, and g consistently increases over the course of odor exposure (FIG. 11E).
[0023] FIG. 12 shows the activation of different glomeruli in response to different odors and concentration of odors. Amyl acetate activated one set of glomeruli (FIG. 12A), while butyraldehyde activated another set of glomeruli (FIG. 12B). When the two odors are presented to the animal simultaneously, fewer glomeruli became activated in response to a lower concentration of 10"2 (FIG. 12C) compared to a concentration of 10"1 (FIG. 12D).
[0024] FIG. 13 shows the G-CaMP2 sequence (SEQ ID NO:1
(polynucleotide sequence) and SEQ ID NO:2 (polypeptide sequence)) and construct used to generate the TetO-G-CaMP2 mouse model of the invention. The G-CaMP2 used by the invention includes 6 HIS tags on the N-terminus and is encoded downstream of an inducible promoter and upstream of a SV40 polyA sequence (FIG. 13A and Fig. 13B). The inducible promoter contains a minimal CMV promoter (CMV miniP) regulated by 4 TetO sequences (tetO) and is separated from G-CaMP2 with a generic intron (FIG. 13B).
DETAILED DESCRIPTION
[0025] The present invention provides compositions and methods to detect and/or measure GES activation caused by, e.g., in vivo calcium (Ca2+) signaling of specific tissues. The compositions and methods provided herein overcome the low signal-to-noise ratio and in vivo limitations associated with prior attempts to detect and/or measure, e.g., intracellular Ca2+ signaling. Specifically, the invention allows combinatorial targeting of specific cell populations using, e.g., a tetracycline-based, inducible, modular transgenic system.
[0026] In a first embodiment of the present invention, there is provided a transgenic mouse comprising a first polynucleotide comprising a GES operably linked to an inducible regulatory element and a second polynucleotide encoding a transactivator of the inducible regulatory element operably linked to a tissue-specific regulatory element, wherein expression of the GES may be detected and/or measured optionally in vivo using a non-invasive technique.
[0027] In the present invention, the GES may be any polypeptide whose physical properties are altered so as to produce a fluorescent signal in the presence of, e.g., specific ions, metabolites or secondary messengers. For example, the GES may be a fluorescence (Forster) resonance energy transfer (FRET)-based sensor or a single fluorescent protein (FP)-based sensor.
[0028] Non-limiting examples of FRET-based sensors that may be used in the present invention include FIP-CBsm, Cameleon-2, Split Cameleon-2, Cameleon- 3, YC2.0, YC4.0, YC2.1 , YC3.1 , YC2.3, YC2.6, YC3.12, YC3.2, YC3.3, YC3.6, YC6.1 , TN-L15, TN-humTnC, TN-XL, Split indicator of cAMP, CGY-DeH , Cygnet-2, cGES-GKIB, CGES-DE2, cGES-DE5, Raichu-Ras, Raichu-Rap1, Raichu-Cdc42,
Raichu-Rac1 , Raichu-CRIB, Cdc42-inidicator, Cdc42-GEFs-indicator, Raichu-RhoA, Raichu-RBD, ART, AKAR1 , Srk-indicator, EGFR-indicator, Abl-indicator, Picchu, Aktus, BKAR, CKAR, EAS-2, EAS-3, and EAS-5. The FRET-based sensors are reviewed in, e.g., Souslova, E.A., and Chudakov, D. M., Genetically Encoded Intracellular Sensors Based on Fluorescent Proteins, Biochemistry (Moscow), 72(7):683-97 (2007).
[0029] Non-limiting examples of single FP-based sensors that may be used in the present invention include Camgaroo-1 , Camgaroo-2, G-CaMP, G-CaMP1.6, G-CaMP2, Cameleon, Troponeon, Flash-Pericam, Split-Pericam, Ratiometric- Pericam, Inverse-Pericam, Case 12, Case 16, Cyan-Sinphos, Green-Sinphos, Yellow-Sinphos, and HyPer. Single FP-based sensors are reviewed in, e.g., Souslova, E.A., and Chudakov, D. M., supra.
[0030] Preferably, the FP-based sensor is a G-CaMP2 indicator. More preferably, the G-CaMP2 indicator is a polypeptide having from about 1 to about 25 His residues at its N-terminus.
[0031] In this embodiment, the regulatory elements - both inducible and tissue-specific - which are defined in further detail below, include nucleotide sequences that encode promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), mRNA, enhancers, splice junctions, and other elements known in the art, which collectively provide for the replication, transcription, post-transcriptional processing and translation of a coding sequence in a recipient cell. Not all of these regulatory elements need always be present so long as the
selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell/tissue.
[0032] By "enhancer sequence" is meant a nucleic acid sequence that, when positioned proximate to a promoter, confers increased transcription activity relative to the transcription activity resulting from the promoter in the absence of the enhancer domain. Accordingly, an "enhancer" includes a polynucleotide sequence that enhances transcription of a gene or coding sequence to which it is operably linked. A large number of enhancers, from a variety of different sources are well known in the art. A number of polynucleotides which have promoter sequences (such as the commonly-used CMV promoter) also have enhancer sequences. [0033] In the present invention, the inducible regulatory element includes at least a polynucleotide sequence selected from a tetracycline- or tetracycline derivative-regulated promoter, a steroid-regulated promoter, and a metal-regulated promoter. Non-limiting examples of inducible regulatory elements that may be used in the present invention include polynucleotide sequences that include at least a tetracycline-responsive promoter, a doxycycline-responsive promoter, a minocycline- responsive promoter, a metallothionine-responsive promoter, an ecdysone- responsive promoter, other steroid-responsive promoters, a rapamycin-responsive promoter, an interferon regulated promoter, a progesterone receptor-derived promoter, and an estrogen receptor derived promoter. Preferably, the inducible regulatory element is regulated by a tetracycline transactivator, such as for example a tTA or a rtTA, as disclosed in further detail below.
[0034] In this embodiment, the tissue-specific regulatory element targets expression of the GES to a desired tissue and/or cell type. In the present invention,
the tissue-specific regulatory element may target expression of the GES to, e.g., neural, epithelial, muscular, connective, brain, skin, intestine, pancreas, kidney, lung, stomach, liver, retinal, esophagus, colon, prostate, ovary, bladder, uterus, and bone. Preferably, the tissue-specific regulatory element targets expression of the GES to neural or brain tissue.
[0035] Tissue-specific regulatory elements, e.g., promoters, are well know in the art and may be used in accordance with the present invention so long as the regulatory element is effective to target and express a polynucleotide of interest (which encodes the transactivator) in a selected tissue and/or cell type. Representative, non-limiting examples of such tissue-specific regulatory elements are set forth below: Neural
[0036] The tissue-specific regulatory element may include a neuronal promoter. Preferably, the tissue-specific regulatory element provides specific expression in the central nervous system (CNS). One example of such a neural- specific regulatory element is the mouse Thy1 promoter (Ingraham, H. A., Lawless, G. M., Evans, G. A. (1986) The mouse Thy-1.2 glycoprotein gene: complete sequence and identification of an unusual promoter. J Immunol. 136, 1482-1489). Other non-limiting examples of a neural-specific regulatory element include a BDNF promoter, a NGF promoter, a growth factor promoter, an axon-specific promoter, a dend rite-specific promoter, a brain-specific promoter, and a hippocampal-specific promoter. Another example of a neuron-specific promoter is a neurofilament promoter (Byrne et al., 1989). Brain
[0037] Non-limiting examples of brain-specific regulatory elements include glial fibrillary acidic protein (GFAP) promoter, Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A., GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci. . 1994; 14: 1030-1037; brain-specific promoter of the human FGF1 gene, Oncogene. 2000 Dec 14;19(54):6229-39. Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brain-specific FGF1 promoter. Chiu IM, Touhalisky K, Liu Y, Yates A, Frostholm A.; calcium-calmodulin- dependent kinase Il (CamKII) promoter, Science. 1996 Dec 6;274(5293): 1678-83. Control of memory formation through regulated expression of a CaMKII transgene. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER; portions of the murine Cyp19 gene promoter, J Steroid Biochem MoI Biol. 2007 Feb; 103(2): 119-28., Epub 2006 Oct 31., 0.2-kb promoter sequence of the murine Cyp19 gene target beta-galactosidase expression to specific brain areas of transgenic mice. Nausch N, Manteuffel G, Vanselow J; portions of the SCN8A promoter, Mamm Genome. 2007 Oct 9; Identification of evolutionarily conserved, functional noncoding elements in the promoter region of the sodium channel gene SCN8A. Drews VL, Shi K, de Haan G, Meisler MH; neuregulin 1 (NRG1) type IV promoter, J Biol Chem. 2007 Aug 17;282(33):24343-51., Epub 2007 Jun 12., Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. Tan W, Wang Y, Gold B, Chen J, Dean M, Harrison PJ, Weinberger DR, Law AJ.; rodent beta-adducin promoter, Nucleic Acids Res. 2006 Jan 9;34(1):243-53. Print 2006. Brain-specific promoter and polyadenylation sites of the beta-adducin pre-mRNA generate an unusually long 3'-UTR. Costessi L, Devescovi G, Baralle FE, Muro AF.; promoter of
exon 1f of aromatase, J Steroid Biochem MoI Biol. 2005 May; 95(1-5):49-55. Analysis of spatiotemporal regulation of aromatase in the brain using transgenic mice. Harada N, Honda S., and J Steroid Biochem MoI Biol. 2001 Dec;79(1-5):255- 60. Characterization and purification of a protein binding to the cis-acting element for brain-specific exon 1 of the mouse aromatase gene. Honda Sl, Matsumoto T1 Harada N.; promoter of brain-specific angiogenesis inhibitor 1 -associated protein, FEBS Lett. 2004 May 21 ;566(1-3):87-94. The promoter of brain-specific angiogenesis inhibitor 1 -associated protein 4 drives developmentally targeted transgene expression mainly in adult cerebral cortex and hippocampus. Kim MY, Ahn KY, Lee SM, Koh JT, Chun BJ, Bae CS, Lee KS, Kim KK.; mouse 14-3-3 eta chain promoter, Brain Res MoI Brain Res. 2002 Apr 30; 100(1 -2): 13-20. Isolation and structure of the mouse 14-3-3 eta chain gene and the distribution of 14-3-3 eta mRNA in the mouse brain. Toyooka K, Muratake T, Watanabe H, Hayashi S, lchikawa T1 Usui H, Washiyama K, Kumanishi T, Takahashi Y.; portions of CD80 promoter, Biochim Biophys Acta. 2000 Feb 29;1490(3):342-7. Expression of CD80 promoter in transgenic mice. Zhang H, Haasch D, Patterson B, Dickinson B, Okasinski GF.; portions of the rat aldolase C gene promoter, J. Biol. Chem., Vol. 269, Issue 6, 4194-4200, Feb, 1994. Analysis of a brain-specific isozyme. Expression and chromatin structure of the rat aldolase C gene and transgenes. I Makeh, M Thomas, JP Hardelin, P Briand, A Kahn and H Skala; portions of the myelin basic protein promoter, EMBO J. 1990 Oct;9(10):3101-8. Core promoter of the mouse myelin basic protein gene governs brain-specific transcription in vitro. Tamura T, Sumita K, Hirose S, Mikoshiba K.; tyrosine hydroxylase promoter, J Neurosci. 1992 Nov;12(11):4460-7: 5' flanking sequences of the rat tyrosine
hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. Banerjee SA, Hoppe P, Brilliant M, Chikaraishi DM. Muscle
[0038] Non-limiting examples of muscle-specific regulatory elements include muscle creatine kinase promoter, MoI Cell Biol. 1988 Jul;8(7):2896-909. Identification of upstream and intragenic regulatory elements that confer cell-type- restricted and differentiation-specific expression on the muscle creatine kinase gene. Sternberg EA, Spizz G, Perry WM, Vizard D, Weil T, Olson EN.; portions of Duchenne muscular dystrophy gene promoter, H J Klamut, S B Gangopadhyay, R G Worton and P N Ray, MoI Cell Biol. 1990 January; 10(1): 193-205, Molecular and functional analysis of the muscle-specific promoter region of the Duchenne muscular dystrophy gene; promoters of the MyoD gene family, Science. 1991 Feb 15;251(4995):761-6. The myoD gene family: nodal point during specification of the muscle cell lineage. Weintraub H, Davis R, Tapscott S, Thayer M, Krause M, Benezra R, Blackwell TK1 Turner D, Rupp R, Hollenberg S, et al.; myocyte-specific enhancer binding factor MEF-2, MoI Cell Biol. 1991 Oct;11(10):4854-62. Myogenin induces the myocyte-specific enhancer binding factor MEF-2 independently of other muscle-specific gene products. Cserjesi P, Olson EN.; portions of human alpha- skeletal actin gene promoter, MoI Cell Biol. 1987 Nov;7(11):4089-99. Multiple 5'- flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression. Muscat GE, Kedes L.; tryponin C promoter, Gene Expr. 1993;3(1):11-25. Tissue-specific restriction of skeletal muscle troponin C gene expression. Gahlmann R, Kedes L.
[0039] A preferred class of muscle-specific regulatory elements is the cardiac-specific regulatory elements. Cardiac-specific promoters include, but are not limited to, promoters from the following genes: an alpha-myosin heavy chain gene, e.g., a ventricular alpha-myosin heavy chain gene, a beta-myosin heavy chain gene, e.g., a ventricular beta-myosin heavy chain gene, a myosin light chain 2v gene, e.g., a ventricular myosin light chain 2 gene, a myosin light chain 2a gene, e.g., a ventricular myosin light chain 2 gene, a cardiomyocyte-restricted cardiac ankyrin repeat protein (CARP) gene, a cardiac alpha-actin gene, a cardiac m2 muscarinic acetylcholine gene, ANP gene, a BNP gene, a cardiac troponin C gene, a cardiac troponin I gene, a cardiac troponin T gene, a cardiac sarcoplasmic reticulum Ca- ATPase gene, a skeletal alpha-actin gene, as well as an artificial cardiac cell-specific promoter.
[0040] Further, chamber-specific promoters or enhancers may also be employed, e.g., for atrial-specific expression, the quail slow myosin chain type 3 (MyHC3) or ANP promoter, or the cGATA-6 enhancer, may be employed. For ventricle-specific expression, the iroquois homeobox gene may be employed. Examples of ventricular myocyte-specific promoters include a ventricular myosin light chain 2 promoter and a ventricular myosin heavy chain promoter. [0041] Other sources for promoters and/or enhancers are promoters and enhancers from the Csx/NKX 2.5 gene, titin gene, alpha-actinin gene, myomesin gene, M protein gene, cardiac troponin T gene, RyR2 gene, Cx40 gene, and Cx43 gene, as well as genes which bind Mef2, dHAND, GATA, CarG, E-box, Csx/NKX 2.5, or TGF-beta, or a combination thereof.
[0042] Tissue-specific enhancers may also be employed. For instance, a preferred atrial-specific enhancer is the cGATA-6 enhancer. In other embodiments, the enhancer is not tissue-specific. Skin
[0043] Non-limiting examples of regulatory elements directing skin-specific transgene expression include keratin promoters such as a K5 promoter, a K6 promoter, or a K14 promoter, or a fragment thereof. These promoters have been used to generate transgenic mice with skin-specific transgene expression (Cataisson et al., J Immunol 171 :2703-2713 (2003); Shibaki et al., J Invest Dermatol 123:109- 115 (2004); Feith et al., Cancer Res 61 :6073-6081 (2001) Vassar et al., Proc Natl Acad Sci USA 86:1563-1567 (1989)). Additionally, U.S. Pat. No. 5,811 ,634 discloses the use of promoter/regulatory sequences of a K1 promoter, a K5 promoter, a K6 promoter and a K10 promoter to direct transgene expression to the cells of the skin in a transgenic non-human mammal. Esophagus
[0044] A non-limiting example of a regulatory element directing esophagus- specific transgene expression is an Epstein-Barr virus (EBV) ED-L2 promoter, or a fragment thereof. The EBV ED-L2 promoter has been used to express a transgene in the cells of the esophagus of transgenic mice (Opitz et al., J Clin Invest 110:61- 769 (2002); Fong et al., Cancer Res 63:4244-4252 (2003)). Liver
[0045] Non-limiting examples of regulatory elements directing liver-specific transgene expression are a major urinary protein (MUP) promoter, or a fragment thereof, an albumin promoter, or a fragment thereof, a transthyretin promoter, or a
fragment thereof, an apoE promoter, or a fragment thereof, or a phenylalanine hydroxylase promoter, or a fragment thereof. These promoters have been used to generate transgenic mice with transgene expression directed to the cells of the liver (Kawamure et al., Hepatology 25:1014-1021 (1997); Kuklin et al., MoI Cancer 3:17- 27 (2004); Nicolas et al., Proc Natl Acad Sci USA 99:4596-4601 (2002); FEBS Lett 555:528-532 (2003); Jackerott et al., Diabetologia 45:1292-1297 (2002)). Colon
[0046] Non-limiting examples of regulatory elements directing colon-specific transgene expression are a villin promoter, or a fragment thereof and a fatty acid binding protein promoter (FABP), or a fragment thereof. These promoters have been used to generate transgenic mice with colon-specific transgene expression (Pinto et al., J Biol Chem 274:6476-6482 (1999); Janssen et al., Gastroenterology 123:492- 504 (2002); Sweetser et al., Proc Natl Acad Sci 85:9611-9615 (1988); Cobb et al., Cancer 100:1311-1323 (2004)). U.S. Application Publication No. US 2003/0177516 discloses the use of the intestinal FABP promoter region to direct transgene expression to the cells of the gut in a transgenic bird. Prostate
[0047] Non-limiting examples of regulatory elements directing prostate- specific transgene expression are a cryptdin-2 promoter, or a fragment thereof, a prostate-specific antigen (PSA) promoter, or a fragment thereof, a C(3)1 promoter, or a fragment thereof, a prostate secretory protein of 94 amino acids (PSP94) promoter, or a fragment thereof, and a probasin promoter, or a fragment thereof. These promoters have been used to generate transgenic mice with prostate-specific transgene expression (Garabedian et al., Proc Natl Acad Sci USA 95:15382-15387
(1998); Cleutjens et al., MoI Endocrinol 11 :1256-1265 (1997); Zhang et al., Prostate 443:278-285 (2000); Gabril et al., Gene Ther 9:1589-1599 (2002); Masumori et al., Cancer Res 61 :2239-2249 (2001)). U.S. Pat. No. 6,136,792 discloses the use of promoter/regulatory sequences of the PSA promoter to direct transgene expression to the cells of the prostate in a transgenic non-human mammal. Additionally, U.S. Pat. Nos. 5,952,488 and 5,907,078 disclose the use of the probasin promoter to drive expression of a transgene specifically in the prostate of transgenic non-human mammals. Ovary
[0048] A non-limiting example of a regulatory element directing ovary- specific transgene expression is the ovarian-specific promoter (OSP-1) or a fragment thereof. This promoter has been used to express a transgene in the cells of the ovaries of transgenic mice (Garson et al., J Soc Gynecol Investig 10:244-250 (2003)). Kidney
[0049] Non-limiting examples of regulatory elements directing kidney- specific transgene expression are the uromodulin promoter, or a fragment thereof, the Tamm-Horsfall protein (THP) promoter, or a fragment thereof, and the type 1 gamma-glutamyl transpeptidase promoter, or a fragment thereof. These promoters have been used to generate transgenic mice with kidney-specific transgene expression (Huang et al., BMC Biotechnol 5:9 (2005); Zhu et al., Am J Physiol Renal Physiol 282:F608-F617 (2002); Terzi et al., J Clin Invest 106:225-234 (2000)). U.S. Pat. No. 6,888,047 discloses the use of the uromodulin promoter to direct transgene expression to the cells of the kidneys in a transgenic non-human mammal. Another
example of a kidney-specific promoter is the Ksp-cadherin promoter (Yun Bai, et al., 2002) or the Sglt2 promoter (Rubera I, et al., 2004). Bladder
[0050] Non-limiting examples of regulatory elements directing bladder- or urothelium-specific transgene expression are the promoters, or fragments thereof, directing expression of the uroplakin genes. The uroplakin Il promoter has been used to engineer transgenic mice with transgene expression specifically in urothelium of the bladder (Cheng Cancer Res 62: 4157-4163 (2002); Lin et al., Proc Natl Acad Sci USA 92:679-683 (1995)). U.S. Pat. Nos. 5,824,453 and 6,001 ,646 disclose the use of the uroplakin Il gene promoter to produce transgenic animals expressing a transgene specifically in the cells of the bladder urothelium. Furthermore, U.S. Pat. No. 6,339,183 discloses transgenic animals in which the urothelium-specific expression of a transgene is directed by a uroplakin Ia promoter, a uroplakin mi promoter, or a urohingin promoter. Uterus
[0051] A non-limiting example of a regulatory element directing uterus- specific transgene expression is the uteroglobin promoter, or fragments thereof. This promoter has been used to engineer transgenic mice with transgene expression specifically in the uterus (Gomez Lahoz et al., Gene 117:255-258 (1992); Sandmoller et al., 9:2805-2815 (1994)).
[0052] Additional exemplary tissue-specific regulatory elements include, but are not limited to, albumin promoters (liver specific; Pinkert et al., 1987), lymphoid specific promoters (Calame et al., 1988), promoters of T-cell receptors (Winoto et al., 1989) and immunoglobulins (Baneriji et al., 1983; Queen and Baltimore, 1983),
intestine-specific promoters (Fabp promoter, Bullard, D. C, et al., 2002), pancreas- specific promoters (Edlunch et al., 1985), or mammary gland-specific promoters (milk whey promoter, U.S. Pat. No. 4,873,316). Developmentally-regulated promoters may also be used, such as the murine homeobox promoters (Kessel et al., 1990) or the alpha-fetoprotein promoter (Campes et al., 1989). [0053] In a preferred embodiment, the tissue-specific regulatory element includes the OMP promoter.
[0054] In another embodiment of the present invention, there is provided a transgenic mouse comprising a first polynucleotide encoding a fluorescent Ca2+ indicator operably linked to an inducible regulatory element and a second polynucleotide encoding a tetracycline transactivator operably linked to a tissue- specific regulatory element. In this embodiment, expression of the fluorescent Ca2+ indicator may be detected and/or measured optionally in vivo using a non-invasive technique.
[0055] In the present invention, the GES, e.g., fluorescent Ca2+ indicator, preferably is G-CaMP2. It is also preferred that the inducible regulatory element comprises a tetracycline promoter and that the tissue specific regulatory element comprises an olfactory marker protein (OMP) promoter.
[0056] The GES, e.g., fluorescent Ca2+ indicator, is detected or measured using conventional methods known in the art and/or as disclosed further herein. As used herein, "detected," "detection," and the like are intended to mean determining whether the GES, e.g., fluorescent Ca2+ indicator, has been activated by the presence of, e.g., Ca2+. As used herein, "measured," measuring," and the like are intended to mean monitoring the level of activation and/or quantitating the level of
activation of the GES, e.g., Ca2+ indicator, and relating that to the concentration of, e.g., Ca2+.
[0057] Such detection and/or measuring may be carried out in vivo using invasive or non-invasive procedures. As used herein, invasive procedures include modifying the animal to enhance detection and/or measurement of a signal generated by the GES, e.g., fluorescent Ca2+ indicator, of the present invention. Invasive procedures include, e.g., thinning the skull of the animal, e.g., transgenic mouse, using conventional methods known in the art and disclosed in more detail herein. Additionally, tissue samples from the transgenic animal, e.g., mouse, may be manipulated ex vivo, in situ, or in vitro. For example, a signal from a GES, e.g., a fluorescent Ca2+ indicator, from a brain slice of a transgenic mouse according to the present invention may be detected and/or measured using conventional methods, including those disclosed herein.
[0058] As used herein, non-invasive procedures include non-surgical and/or minimally invasive procedures for positioning, detecting, and/or measuring a signal generated by a GES, e.g. a fluorescent Ca2+ indicator, of the present invention. [0059] Another embodiment of the invention is a method for identifying a candidate compound that modulates intracellular calcium signaling. This method comprises providing a candidate compound, providing a transgenic mouse according to the present invention, administering the candidate compound to the transgenic mouse, and evaluating an effect, if any, of the candidate compound on intracellular calcium signaling.
[0060] In this embodiment, "modulates," "modulation," and the like means either an increase or decrease in intracellular calcium signaling compared to a
transgenic mouse treated with a control. In the present invention, "candidate compound" is to be broadly interpreted and includes a biological and/or non- biological agent. For example, the candidate compound may be a nucleic acid, polypeptide, polysaccharide, or small organic or inorganic molecule. Candidate compounds may include a fusion protein, an antibody, antibody mimetic, domain antibody, targeted aptamer, RNAi, siRNA, shRNA, or an antisense sequence. [0061] The candidate compound may be administered to the transgenic mouse in any convenient manner. For example, the candidate compound may be administered to the transgenic mouse orally, parenterally, sublingually, transdermal^, rectally, transmucosally, topically, via olfaction, via buccal administration, or combinations thereof. Parenteral administration may be intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, or intraarticular. Preferably, the candidate compound is administered to the transgenic mouse through olfaction. As used herein, administration through olfaction means that the candidate compound is presented to the transgenic mouse in such a manner that the candidate compound is inhaled.
[0062] In another aspect of the invention, the candidate compound may be administered to the transgenic mouse by delivering it directly to a tissue sample. For example, a brain slice from a transgenic mouse according to the present invention may be bathed in a solution containing the candidate compound. Other analogous methods well known in the art may be used as well.
[0063] In this embodiment, evaluating an effect, if any, of the candidate compound on intracellular calcium signaling means determining whether the candidate compound increased, decreased, or had no effect on intracellular calcium
signaling in a specific tissue, such as, e.g., the olfactory bulb (OB), main olfactory epithelium (MOE), or vomeronasal organ (VNO). Methods for carrying out such evaluations are known in the art and disclosed further herein. [0064] In this embodiment, the evaluation step may be carried out in vivo, through a tissue of the transgenic mouse in a non-invasive procedure as disclosed previously. Preferably, the non-invasive procedure is carried out through the skull of the transgenic mouse without thinning or otherwise decreasing the thickness of the skull.
[0065] Alternatively, the evaluation step may be carried out in vivo through a tissue of the transgenic mouse in a more invasive procedure by, e.g., thinning or otherwise decreasing the thickness of the skull. Procedures for thinning the skull of a mouse are known in the art and further disclosed in the Examples below. Preferably, in this aspect of the invention, the thickness of the skull at a particular site is decreased by, e.g. shaving the skull as disclosed herein, to a thickness less than about 150 μm, preferably less about than 100 μm, more preferably less than about 75 μm, such as for example between about 40-60 μm, including 50 μm. [0066] In this embodiment, the evaluating step may also be carried out on tissue obtained from the brain of a transgenic mouse according to the present invention. For example, the evaluating step may be carried out on a brain slice. Tetracycline Inducible System
[0067] The present invention will now be described with reference to a preferred embodiment that exemplifies a tetracycline-based inducible system. The tetracycline (tet) inducible system uses regulatory elements from the Tn70-encoded tetracycline resistance operon from E. coli that can be regulated by tet. The
tetracycline inducible system utilized by the invention includes two components: 1) a transactivator protein (tTA) to regulate gene expression and 2) an inducible regulatory element containing multiple tetracycline resistance operon (tetO) sequences placed upstream of a gene of interest. The tetracycline transactivator protein is a chimeric protein that consists of a fusion between the herpes simplex virus-transactivating domain VP16 and the tetracycline repressor from E. coli. The function of a tTA is to be sensitive to tetracycline and tetracycline derivatives. Such derivatives include doxycycline and minocycline. In the absence of tet or a derivative, tTA binds to the tetO sequences upstream of the gene of interest and activates transcription. In the presence of tet or a derivative, a conformational change in the tetracycline repressor prevents the binding of tTA to tetO and prevents transcription. This system has been used both in vitro and in vivo (Fruh et al. 1994; Wimmel et al. 1994; Furth et al. 1994; and Kistner et al. 1996, all incorporated herein by reference). Alternatively, a reverse transactivator (rtTA), which binds a tetO sequence in the presence of tet, may also be used in place of tTA. A skilled artisan will appreciate that the transactivator used depends upon the intended use of the invention.
[0068] In the present invention, the two components of the tet inducible system may be provided in two separate modules. The term "module", as used herein, refers to a subject having within its genome one component, or construct, that is part of a multi- component, or construct, system. One module provides the transactivator protein targeted to specific tissues of an organism (e.g., OMP-tTA line), and the other module provides the fluorescent Ca2+ indicator G-CaMP2 under the control of a tetracycline inducible promoter (G-CaMP2 line). A skilled artisan will
recognize that these modules extend the versatility of the invention by providing an interchangeable tissue-targeting component. The modules may be any subject, organism, or animal having a central nervous system. Suitable modules include: mammals, humans, mice, rats, dogs, cats, cattle, swine, sheep, and ungulates; preferably the modules are mice or rats; and more preferably the modules are mice. Calcium Sensor Module
[0069] The first module of the present invention is exemplified by a tetracycline inducible system, which includes a transgenic mouse that harbors a GES, e.g., a fluorescent Ca2+ indicator protein (FCIP), encoded downstream of a tet inducible promoter containing tetO sequences. The FCIP, G-CaMP2 (provided by J. Nakai, Laboratory for Memory and Learning, Saitama, Japan), was cloned downstream to the tet inducible promoter using molecular cloning methods known in the art (see, Current Protocols in Molecular Biology, Unit 1.5, pub, John Wiley & Sons, Inc., 1998 and incorporated herein by reference). The resulting nucleic acid was used to generate a transgenic mouse line by introducing the transgene- encoding nucleic acid sequence into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection, or other suitable techniques). The oocyte was placed in a pseudo-pregnant female foster animal and allowed to develop into a viable animal. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are disclosed, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191 ; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, and N. Y. The TetO-G-CaMP2 transgenic mouse may be crossed with any mouse targeting the activating tTA to a
specific tissue in order to evaluate calcium fluctuations and responses in the desired target tissue. For example, the TetO-G-CaMP2 transgenic mouse may be crossed with a mouse targeting tTA to the skin to study calcium fluctuations of keratinocytes as they differentiate or with a mouse targeting tTA to motor neurons to study their communication.
[0070] The FCIP encoded by the transgene is G-CaMP2, which is a variant of G-Camp. G-CaMP2 contains several mutations and alterations that enhance folding, stability, and fluorescence at physiological temperatures compared to Camp. Nevertheless, expression of G-CaMP2 in vivo has been varied. For example, modest success was achieved in mouse heart muscle by combining surgical exposure of the heart with monitoring G-CaMP2 expression (Tallini, Y. N., et al., 2006). Invasive surgery or sacrifice was required to monitor expression. In an alternative system, G-CaMP2 was used to study calcium signaling in cerebellar parallel fibers of the mouse brain (Diez-Garcia, J., et al., 2005). Temporal control of expression was not achieved in the Diez-Garcia brain model and monitoring could only be achieved in vitro.
[0071] The present invention overcomes the deficiencies of the previous models by achieving much greater intensity of expression such that G-CaMP2 expression can be advantageously monitored in vivo without animal sacrifice or invasive, life-threatening, surgical procedures (see, e.g., FIGS. 9 and 10). Not wishing to be bound by a particular theory, it is possible that the robust expression of the present invention is, in part, due to the particular regulatory element and overall configuration used to create the construct used. A skilled artisan will recognize the difficulty associated with generating mice that express, e.g., a Ca2+ sensor at a level
to detect the sensor through an opaque tissue such as the bone. Neither the heart model (Tallini, Y. N., et al., 2006) nor the brain model (Diez-Garcia, J., et al., 2005) achieved the high expression necessary for detection through an opaque tissue. [0072] The invention provides high expression capable of real-time detection that is a vast improvement over other models described in the art. Further, the G- CaMP2 transgenic mouse of the invention not only can be temporally controlled, but it may also be combined with interchangeable transgenic mice targeting a tetracycline transactivator (tTA or rtTA) to a specific tissue or population of cells to produce compound transgenic mice in which Ca2+ signaling may be studied in a multitude of targeted tissues or cells.
[0073] The high expression may be the result of using a CMV minimal promoter regulated by 4 tetO sequences to drive G-CaMP2 expression, the addition of 6 HIS tags to the N-terminus of G-CaMP2, or the combination of the two (see, FIG. 13A and 13B). One skilled in the art will appreciate that the expression level achieved by the invention may be improved or lessened with the addition or removal of one or more HIS tags or regulatory tetO sequences. For example, at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, or even 25 HIS tags, or respectively tetO sequences, may be useful to either increase or decrease expression such that it is measurable above background autofluorescence. Likewise, a different minimal promoter regulated by the tetO sequences may also be used to alter the expression level achieved by the invention. A suitable promoter includes any ubiquitous promoter such as, but not limited to ubiquitinase, β-actin, GAPDH, β-kinesin, ROSA, and phosphoglycerate kinase promoters. A skilled artisan will also recognize that a combination of alterations may result in an overall
change in expression level and the expression level desired depends upon the intended use of the invention. Tissue Targeting Module
[0074] The second module of the tetracycline inducible system is a transgenic mouse that expresses the tTA protein in a specific tissue or population of cells. It is envisioned that tissue-specific regulatory elements that may be used with the invention include those identified above. For example, to target tTA expression to sensory neurons, the tTA gene (tetR and VP16) was inserted in the 3' untranslated DNA sequence flanking the OMP gene, such that its translation was directed by an internal ribosome entry site (IRES) (FIG. 3A). Cells that activate OMP gene transcription, express a bicistronic RNA encoding both OMP and tTA as described in Yu et al. 2004. One of skill in the art will recognize that the tTA protein can be targeted to any specific tissue by encoding it downstream of any tissue- specific regulatory element. It may also be advantageous to target the tissue ubiquitously using an ubiquitous regulatory element, particularly if a temporally- related event, such as development or reproduction, is being evaluated. A skilled artisan will recognize that the tissue-specific regulatory element could be any regulatory element known in the art and is not limited to tissue-specific or ubiquitous regulatory elements, but also may include engineered regulatory elements. "Compound" Transgenic Mice of the Present Invention
[0075] The present invention provides a method to generate a "compound" transgenic mouse that expresses G-CaMP2 in a targeted tissue or population of cells. The invention does not extend to compound transgenic mice made or known by others or to methods or compositions using them. The compound transgenic
mouse line encodes both the G-CaMP2 downstream of an inducible regulatory element and a transactivator downstream of a tissue-specific regulatory element. Exemplary inducible and tissue-specific regulatory elements provided herein are different from each other; however, depending upon the objectives to be achieved, the two promoters may be the same or variants of each other. [0076] To produce the compound transgenic mouse line, the first module of the invention, a transgenic mouse encoding G-CaMP2 downstream of an inducible regulatory element, is combined with the second module of the invention, a transgenic mouse encoding a transactivator downstream of a tissue-specific regulatory element. The modules are combined by breeding or crossing the two mouse lines. For example, a TetO-G-CaMP2 transgenic mouse (tet-G2) may be crossed to an OMP-IRES-tTA transgenic mouse to generate an OMP-tTA-G-CaMP2 compound transgenic mouse. The resultant compound offspring may be identified through Polymerase Chain Reaction (PCR) or Southern blot screening of genomic DNA as known in the art (see, Metzger et a/., 2002).
[0077] The tet-G2 containing mice may be generated by, e.g., mating
C57BL/6 wildtype females to males with the tet-G2 allele. Male mice containing both tet-G2 and OIVT alleles were used to generate 300 embryos in a week. The resulting embryos have both tet-G2 (in 50% of the embryos) and OIVT (in 100% of the embryos). These tet-G2 mice have been deposited under the terms of the Budapest Treaty as disclosed in more detail below.
[0078] Transgene expression and expression patterns may be screened using methods such as protein analysis by Western blot; RNA analysis by Northern blot or quantitative RT-PCR, histological analysis, or other methods commonly
practiced in the art. Depending on the transactivator used, transgene leakage may be determined by treating (for tTA) or not treating (for rtTA) compound transgenic mice with a tetracycline derivative prior to screening for transgene expression. For example, compound transgenic mice using the tTA transactivator may be treated for about 1-3 weeks with about 0.1 , 0.5, 0.75, 1 , 1.5, 2, 5, 7, or 10 mg/mL of doxycycline added to drinking water. An increase in transgene expression in the presence of doxycycline indicates transgene leakage. Lines that show a high level of expression with little or no leakage are preferred. Fluorescence Intensity
[0079] An advantage to the present invention is the production of very bright fluorescence by the selected GES, e.g., G-CaMP2, in response to stimuli that allows detection and/or measurement, e.g., in vivo without invasive surgical procedures or implants. For example, fluorescence in Line 5 mice (see FIGS. 9 and 10) is easily visible through the skull to the naked eye. Thus, animals of the present invention can be used without life-threatening trauma or high risk of infection. The subject transgenic mouse, upon stimulation, shows substantially greater fluorescence intensity, or brightness, in a cell with an increase of calcium influx/eflux compared to a reference cell without an increase in calcium influx/eflux.
[0080] For example, a sensory neuron of an OMP-tTA-G-CaMP2 compound transgenic mouse will exhibit an increase in fluorescence intensity upon stimulation compared to a non-stimulated neuron. It is envisioned that the increase in fluorescence intensity upon stimulation is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% (or two-
fold), at least about 150%, at least about 2X, 3X, 4X, 5X, 1OX, 15X, 20X1 25X, 30X1 40X, 50X1 75X1 100X1 or more, brighter in a stimulated cell compared to a non- stimulated reference cell. Methods of detecting and/or measuring brightness or fluorescence intensity are commonly known in the art. Brightness may be detected and/or measured using techniques including, but not limited to, visual screening, spectrophotometry, spectrofluorometry, fluorescent microscopy, and fluorescence activated cell sorting (FACS). Tracing Neuronal Circuitry
[0081] It is envisioned that the transgenic animals, e.g., mice, of the invention can be used to trace neuronal circuitry. Understanding the pattern of interconnections of specific neural cells is essential to understanding their roles in nervous system function and dysfunction. Traditionally, the connections a neuron makes have been identified using electrophysiological recordings, from histochemical techniques or through the use of anterograde or retrograde tracers that make it possible to visualize the patterns of projections of individual neurons. While these approaches have been useful to identify certain aspects of neural connectivity, their invasiveness, unavoidable confounding artifacts, limitation of resolution in space and time, and the inability to reproduce findings with great fidelity limit their utility.
[0082] The transgenic mice (e.g., OMP-tTA-G-CaMP2) of the invention utilize a sensory neuron-specific regulatory element that allows the tracing of sensory neuron connections. The mapping of neuronal circuits can be achieved by a stimulation that results in intracellular calcium fluctuations. Neural activity, following stimulation, can be monitored through fluorescence imaging and facilitates the
mapping of functional neuronal circuits in the complex environment of the brain. For example, OMP-tTA-G-CaMP2 transgenic mice can be stimulated with an odor, such as acetylcholine, ethyl salicylate, 2-butanone, butyraldehyde, hexyl alcohol, butyric acid, hexonoic acid, or limonene. The odor can be presented locally in the olfactory bulb to induce the fluorescence of the G-CaMP2 sensor. The level of fluorescence intensity can be analyzed through fluorescent imaging of sectioned brain tissue or through the full thickness of the skull. Alternatively, the animals can be anesthetized and their skulls thinned to allow in vivo tracing of neuronal projections with fluorescent microscopy.
[0083] A skilled artisan will appreciate that calcium signaling can be traced in other tissues by interchanging the OMP-tTA line used to generate the OMP-tTA-G- CaMP2 compound transgenic line with another specific tissue targeting tTA mouse line. For example, a transgenic mouse line targeting tTA expression to the skin using a skin specific promoter may be crossed to the TetO-G-CaMP2 line to generate a skin specific G-CaMP2 compound mouse in which calcium signaling in the skin can be traced. Other tissues in which it will be desirable to trace calcium signaling include the kidney, muscle, intestine, and those in which cell motility, communication, or signaling is of interest. Pathological Disease And Identification of Candidate Compounds
[0084] It is envisioned that the invention can be used to measure calcium signaling, cell communication, and cell motility in models of pathological disease or subjects having such disease. One of skill in the art will recognize that there are numerous models of disease, e.g. mouse models, that are used to study the disease process, study mechanics of the disease, and to test or screen potential therapies,
including identification of candidate compounds for modulating such diseases and underlying physiological conditions as disclosed above. Such disease models include, but are not limited to, mouse models of airway hyper-responsiveness (De Sanctis et al. 1995), alcohol and morphine preference (Berretini et al. 1994; Crabbe et al. 1994), atherosclerosis (Hyman et al. 1994), epilepsy (Frankel et al. 1994), and obesity (West et al. 1994). The invention may also be used in models using other organisms having a central nervous system such as cats, dogs, rats, guinea pigs, and ungulates. A skilled artisan will recognize that many models of human disease are available including, but not limited to, those of Alzheimer's disease, Parkinson's disease, many types of cancer, retinal degeneration, inflammatory bowel disease, diabetes, autoimmunity, atherosclerosis, hypertension, and many more. [0085] The transgenic mouse of the invention may be used in combination with any mouse model of human disease to study, e.g., the role calcium plays in that disease. The TetO-G-CaMP2 transgenic mouse may be crossed to any transgenic mouse encoding a tetracycline transactivator protein (tTA or rtTA) targeted to a specific tissue or ubiquitously expressed. The resultant compound transgenic mouse, encoding both the transactivator protein and the inducible G-CaMP2, may then be crossed to the desired mouse model of human disease. A skilled artisan will recognize that the use of a tissue-targeted or ubiquitously expressed transactivator protein depends upon the disease being studied as well as the intended use of the invention. For example, if the mouse model of human disease provides the study of polycystic kidney disease, then it may be advantageous to target the expression of G-CaMP2 to the kidney or to the specific cell of the kidney affected by polycystic kidney disease. But, if the mouse model of human disease provides the study of
cancer affecting multiple tissues, then it may be advantageous to ubiquitously express G-CaMP2.
[0086] Once a mouse model of human disease has been crossed to also express inducible G-CaMP2 (MHD-G-CaMP2), it may be used to study calcium- involved events (and alterations to these events due to disease) including, but not limited to, calcium signaling, cell communication, and cell motility. Methods to study the M H D-G-CaM P2 mouse model include those disclosed herein and others known in the art. A skilled artisan will recognize that the methods used to study the MHD- G-CaMP2 mouse model depend upon the disease, targeted tissue, and the intended use of the invention. Development
[0087] It is envisioned that the invention can be used to study, e.g., calcium signaling, signal transduction, cell communication, and cell motility in development and aging models. One of skill in the art will recognize that there are presently many models available commercially or otherwise that may be used to study the development or aging process. Exemplary models may include, but are not limited to, those that over express, inhibit, eliminate, or otherwise alter the expression (tissue-targeted or ubiquitous) of developmental regulators such as those involved in WNT signaling, Hedgehog signaling, BMP signaling, and other signaling pathways or apoptosis. The invention may be used in models using a variety of organisms having a central nervous system such as mice, cats, dogs, rats, guinea pigs, and ungulates. A preferred model is a mouse. A skilled artisan will recognize that the model selected depends upon the intended use of the invention.
[0088] The transgenic mouse of the invention may be used in combination with any mouse model to study the role of, e.g., calcium in the developmental or aging process. The TetO-G-CaMP2 transgenic mouse may be crossed to any transgenic mouse encoding a tetracycline transactivator protein (tTA or rtTA) targeted to a specific tissue or ubiquitously expressed. The resultant compound transgenic mouse, encoding both the transactivator protein and the inducible G- CaMP2, may then be crossed to the desired mouse model (MM-G-CaMP2). A skilled artisan will recognize that the use of a tissue-targeted or ubiquitously expressed transactivator protein depends upon the disease being studied as well as the intended use of the invention. For example, if the mouse model provides loss of function or over expression of a protein in only the skin, then it may be advantageous to target the expression of G-CaMP2 to the skin or a specific cell of the skin. But, if the mouse model provides the loss of function or over expression of a protein in multiple tissues, then it may be advantageous to ubiquitously express G-CaMP2. [0089] Once a mouse model has been crossed to also express an inducible
GES, such as G-CaMP2 (MM-G-CaMP2), it may be used to study, e.g., calcium- involved events (and alterations to these events) including, but not limited to, calcium signaling, signal transduction, cell communication, and cell motility. Methods to study the MM-G-CaMP2 mouse model include those described herein and others known in the art. A skilled artisan will recognize that the methods used to study the MM-G-CaMP2 mouse model depend upon the disease, targeted tissue, and the intended use of the invention. For example, to study the development process, mice must be time-mated to allow embryos at different stages throughout development to be studied. Methods for studying mouse development are known in the art (see,
Kaufman, M. H., 1999; and Rossant, J., 2002). Likewise, to study the aging process, mice must be allowed to age and analyzed at various stages during the aging process. Methods for studying mouse aging are known in the art (see, Hasty P. et al., 2003).
DEFINITIONS
[0090] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd Ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them.
[0091] A "fluorescent Ca2+ indicator" or "FCIP" is a fusion protein based on the fusion of a fluorescent protein with a Ca2+ sensitive protein. The binding of Ca2+ to the Ca2+ sensitive protein results in a conformational change of the fusion protein that in turn results in fluorescence. The Ca2+ sensitivity of the fluorescence readout of FCIPs is generally achieved either via changes in the efficiency of fluorescence resonance energy transfer between two spectral variants of fluorescent proteins or via changes in the pKa of circularly permuted spectral variants of fluorescent proteins.
[0092] As used herein, a "transgenic mouse" is a mouse, in which one or more of the cells of the animal include a transgene.
[0093] A "transgene" is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.
[0094] "Subject", "organism", or "animal" as used herein means a living being having a central nervous system. Suitable subjects include: mammals, humans, mice, rats, dogs, cats, cattle, swine, sheep, and ungulates. [0095] An "inducible system" refers to the components necessary to allow temporally controlled expression of a gene of interest. Typically, an inducible system includes an "inducible promoter" that is engineered to contain binding sites for specific substrates not present endogenously. For example, the tetracycline-based inducible system is based on regulatory elements from the Tn70-encoded tetracycline resistance operon from E. coli that can be regulated by tetracycline or derivatives of tetracycline. The tetracycline inducible system uses a tetracycline transactivator protein (tTA), tetracycline resistance operon nucleic acid sequences from E. coli (tetO), and tetracycline or a derivative thereof. In the absence of tetracycline, the tTA protein binds to tetO sequences placed upstream of a gene of interest to activate transcription. In the presence of tetracycline, the tTA protein is unable to bind to tetO sequences and transcription is prevented. [0096] A "tetracycline transactivator" is a protein that has the ability to bind to tetracycline resistance operon (tetO) sequences to activate transcription and is tetracycline sensitive.
[0097] The term "tissue-specific regulatory element" means that a given polynucleotide sequence, e.g. a promoter, is transcriptionally active (i.e., directs, the expression of linked sequences sufficient to permit detection of the polypeptide product of the promoter) in less than all cells or tissues of an organism. A tissue- specific regulatory element, which may include a promoter, is preferably active in only one cell type, but may, for example, be active in a particular class or lineage of cell types (e.g., hematopoietic cells). A tissue-specific regulatory element useful according to the invention comprises those sequences necessary and sufficient for the expression of an operably linked nucleic acid sequence in a manner or pattern that is essentially the same as the manner or pattern of expression of the gene linked to that promoter in nature. As noted above, any tissue-specific transcriptional regulatory element known in the art may be used with the invention. Such regulatory elements may be used alone (i.e., a promoter only) or in combination with other regulatory elements.
[0098] The term "ubiquitous regulatory element" refers to any regulatory element, including a promoter, natural or engineered, that displays strong activity in a wide range of cells, tissues and cell cycles. Exemplary ubiquitous promoters include, but are not limited to, ubiquitinase, CMV, β-actin, GAPDH, β-kinesin, ROSA, and phosphoglycerate kinase promoters.
[0099] The term "operably linked" or "operatively linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other. For example, a regulatory element, such as a promoter, is operably linked with a coding sequence when it is capable of regulating the expression of that coding sequence (i.e., that the coding sequence is
under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory elements in a sense or antisense orientation. In another example, the complementary RNA regions of the invention can be operably linked, either directly or indirectly, 5' to the target mRNA, or 3' to the target mRNA, or within the target mRNA, or a first complementary region is 5' and its complement is 3' to the target mRNA. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.
[0100] The term "population of cells" refers to one or more cells arising from at least one stem cell. This includes intact tissue, fractionated/homogenized tissue, cells derived from a tissue, and stem cell cultures isolated from a tissue. [0101] The term "expression", as used herein, refers to the production of a functional end product.
[0102]The term "module", as used herein, refers to a subject having within its genome one component, or construct, that is part of a multi-component, or construct, system. Herein, a module can be a transgenic animal, such as a "transgenic mouse" having at least one construct inserted into its genome. A "compound transgenic mouse" or "transgenic mouse model," which phrases may be used interchangeably herein as the context dictates, has at least two constructs inserted into its genome. For example, the tetracycline inducible system is a binary system that depends upon two constructs: one encoding a transactivator protein, and one encoding a gene of interest downstream of an inducible promoter containing tetO sequences. The two constructs, or modules, work together to produce inducible regulation of the expression of the gene of interest. Each module can be used interchangeably with
other modules that provide either the transactivator protein targeted to one of many
tissues, or one of many genes of interest.
[0103] The invention now being generally described, it will be more readily
understood by reference to the following examples, which are included merely for
purposes of illustration of certain aspects and embodiments of the present invention,
and are not intended to limit the invention.
EXAMPLES
Example 1 In Vitro Mammalian Expression of G-CaMP2
[0104] Early versions of G-CaMP were not ideal for mammalian expression
systems because they, inter alia, did not fold correctly at physiological temperatures.
G-CaMP2, however, is thermally stable and retains brightness at 37°C. These properties of G-CaMP2 were analyzed in vitro using a mammalian expression
system. To test the properties of G-CaMP2, human embryonic kidney cells (HEK
293) were transfected with a plasmid containing G-CaMP2 (pN1-G-CaMP2) and
incubated at 370C for 48 hours. Cells expressing G-CaMP2 exhibited basal levels of
fluorescence when excited at 488 nm. Acetylcholine was then used to activate G-
protein coupled muscarinic acetylcholine receptors and mobilize intracellular
calcium. After treatment with 10 μM acetylcholine, cells expressing G-CaMP2
exhibited an increase in fluorescence, thus allowing an increase in intracellular
calcium to be visualized.
Example 2
TetO G-CaMP2 Construction
[0105] The properties of G-CaMP2 make it an ideal GES to use to monitor calcium fluctuations in vivo in multiple cell types. In order to increase the ease of using G-CaMP2 in multiple cell types, G-CaMP2 was combined with an inducible system with independent targeting potential. The tetracycline inducible system provides tissue-specific targeting separate from the gene of interest, so multiple cell types may be targeted by only changing one component of the system instead of both components.
[0106] The gene of interest component of the tetracycline inducible system was generated by placing the expression of the G-CaMP2 sensor under the control of the tetracycline promoter (TetO-G-CaMP2) using standard genetic engineering methods (FIG. 3B). The G-CaMP2 used by the invention includes a N-terminal HIS tag of 6 HIS residues (FIG. 13A and 13B). The tetracycline promoter contains a minimal CMV promoter regulated by 4 tetO sequences (FIG. 13A and 13B). Transcription of the resulting construct is active in the presence of tTA; therefore, the functionality of the construct was tested in the presence and absence of tTA in a mammalian expression system.
[0107] Human embryonic kidney cells (HEK 293) were co-transfected with
TetO-G-CaMP2 and a construct containing a tetracycline transactivator protein under the control of a ubiquitous promoter (CMV-VP22-tTA). The cells were incubated at 37°C for 48 hours and approximately 40% of the transfected cell population exhibited fluorescence when excited at 488 nm (FIG. 1A). When this population of cells was challenged with 10 μM acetylcholine to activate G-protein coupled muscarinic acetylcholine receptors to mobilize intracellular calcium, a subset of cells responded
with a robust increase in fluorescence (FIG. 1 B, arrows A, B, and C). The increase
in fluorescence observed in cell A was approximately 90 AFU (FIG. 2A), cell B was
approximately 95 AFU (FIG. 2B), and cell C had an increase of approximately 50
AFU (FIG. 2C). The change in fluorescence indicated proper function of the G-
CaMP2 sensor combined with the tetracycline inducible system.
Example 3 Generation of TetO-G-CaMP2 Mouse
[0108] A TetO-G-CaMP2 mouse was generated by linearizing the TetO-G-
CaMP2 construct using restriction enzymes. The linearized construct was injected
into the pronuclei of fertilized eggs placed in a surrogate mother. From three
independent injections, 14 founder mice carrying the transgene were identified by PCR of tail extracted DNA. The 14 founder mice were crossed to a mouse from the
OMP-IRES-tTA line (FIG. 3A), which expresses tTA from the OMP allele, targeting it
to sensory neurons (FIG. 7A and 7B). The levels of transgene expression were
analyzed in compound offspring of the crosses by examining the number of cells that
expressed G-CaMP2 in the olfactory epithelium or the vomeronasal organ. The
intensity of fluorescence from individual cells was also assessed as an indicator of
the level of expression. G-CaMP2 expression in founder Line 1 (FIG. 4A), Line 3
(FIG. 4B), Line 4 (FIG. 4C), Line 5 (FIG. 4E), Line 8 (FIG. 4D), and Line 10 (FIG. 4F)
was at detectable levels with Lines 5 and 10 exhibiting the highest expression levels.
The high expression levels allow expression to be detected at the gross level (FIG.
8A) and cellular level (FIG. 8B and 8C). For example, fluorescence by Line 5 mice was visible through the skull to the naked eye.
Example 4 Monitoring Olfactory Neuron Stimulation
[0109] The compound transgenic mice ("transgenic mice") containing the G-
CaMP2 indicator targeted to the olfactory neurons may be used to evaluate neuron stimulation and map the signals sent in the brain. The response of sensory neurons was analyzed by stimulating transgenic mice with odor of varying concentrations. After anesthetizing mice with an injection of ketamine, the skin over the olfactory bulb was removed and the underlying skull covering the olfactory bulb was surgically thinned. The mice were then secured on an imaging plate and placed underneath a fluorescent microscope for imaging analysis. Background fluorescence was detected before odor stimulation (FIG. 5A). The odor of amyl acetate, delivered to the nose of the mouse, resulted in several glomeruli activating G-CaMP2 fluorescence (FIG. 5B). The odor of octanal also resulted in the response of several glomeruli to activate G-CaMP2 fluorescence (FIG. 5C). Amyl Acetate of various concentrations was also delivered to the nose of the animals using a custom made olfactometer. The resulting quantitative analysis of the response indicated that both the right and left olfactory bulbs were similarly stimulated (FIG. 6). Odor delivery excited the sensory neurons, which generated action potentials that reached both olfactory bulbs.
[0110] Different odors were found to activate different sensory neurons.
OMP-tTA-G-CaMP2 mice were presented with three different odors that resulted in three different subsets of neurons becoming activated. Amyl acetate activated different neurons (FIG. 9A and 12A) than those activated by butyraldehyde (FIG. 9B and 12B) or hexanoic acid (FIG. 9C). When OMP-tTA-G-CaMP2 mice were
presented with the combination of amyl acetate and butyraldehyde odors different
glomeruli were activated (FIG. 12C and 12D), than when either odor was presented
alone (FIG. 12A and 12B, respectively). The concentration of odor presented also
activated glomeruli in a dose dependent manner (FIG. 12C and 12D).
[0111] The length of odor exposure to different odors resulted in different
expression profiles of neurons. The odor of octanal activated several different
glomeruli sequentially (FIG. 1OA, 1OB, 10C, and 10D) and as the sequence
progressed, the neurons initially activated exhibited a decrease in G-CaMP2 expression (FIG. 10C, 10D1 and 10E). The odor of butyraldehyde also sequentially
activated glomeruli (FIG. 11 A, 11 B, 11C, and 11 D). But, as the sequence
progressed, the intensity of G-CaMP2 expression continued to increase (FIG. 11E).
EXAMPLE 5 Live animal imaging protocol
[0112] Animals are anesthetized with Ketamin/Xylazine cocktail and the
righting reflex of the hind limbs are tested prior to surgery. Once deeply
anesthetized, the hair over the head is shaved with a razor blade and a midline
incision is made in the skin covering the skull to expose the olfactory bulb. For direct imaging, a head holder is glued to the bone and the animal is mounted to the
microscope stage with the olfactory bulb region positioned right under the lens.
(FIGS. 9 and 10). For bone thinning imaging, micro dental tools wet with saline are
used to scrape the surface of the bone covering the olfactory bulb. Occasional air
puffs are used to cool the thinning surface to prevent heat damage of the brain
tissue. We normally stop when the bone can be indented by the gentle tough of a
forceps tip, which is about 50 μm thick. The surface is then gently cleaned with saline and the head holder is attached for mounting the animal to the microscope.
DEPOSIT
[0113] Tet-G2 transgenic embryos of the invention were deposited with the
Patent Depository of the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, USA (ATCC) on October 23, 2007 and assigned Patent
Deposit No. . These deposits were made under the provisions of the
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Applicant and ATCC, which assures permanent and unrestricted availability of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the deposit to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).
[0114] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art
from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
CITED DOCUMENTS
[0115] The following documents, as well as those cited within this specification, are specifically incorporated by reference to the extent that they provide or teach exemplary methodology, techniques and/or compositions supplemental to those employed herein.
1. Baneriji et al., Ce// 33:729-740, 1983
2. Berrettini, W.H., T.N. Ferraro, R.C. Alexander, A.M. Buchberg, and W.H. Vogel. 1994. Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nature Genet. 7: 54-58.
3. Bullard, D. C, et al., Am. J. Physiol. Gastrointest. Liver Physiol. 283:G1232- G 1237, Dec. 2002
4. Byrne et al., Proc. Natl. Acad. Sci. USA 86:5473-5477, 1989
5. Calame et al., Adv. Immunol. 43:235-275, 1988
6. Campes et al., Genes Dev. 3:537-546, 1989
7. Current Protocols in Molecular Biology, Unit 1.5, pub, John Wiley & Sons, Inc., 1998.
8. Crabbe, J. C, J. K. Belknap, and K.J. Buck. 1994. Genetic animal models of alcohol and drug abuse. Science 264: 1715-1723.
9. De Sanctis, G.T., M. Merchant, D.R. Beier, R.D. Dredge, J. K. Grobholz, T.R. Martin, E. S. Lander, and J. M. Drazen. 1995. Quantitative locus analysis of
airway hyperresponsiveness in A/J and C57BL/6J mice. Nature Genet. 11 : 150-154.
10. Diez-Garcia, J., et al. Eur. J. Neurosci. 22:627-635, 2005
11. Edlunch et al., Science 230:912-916, 1985
12. Frankel, W.N., B.A. Taylor, J. L. Noebels, and CM. Lutz. 1994. Genetic epilepsy model derived from common inbred mouse strains. Genetics 138: 481-489.
13. Fruh, K., et al. EMBO J. 13:3236-3244, 1994
14. Furth, P.A., et al. PNAS 97:9302-9306, 1994
15. Fussenegger M., Biotechnol. Prog. 17: 1-51 , 2001
16. Go, W. Y. and Ho, S. N., J. Gene Med. 4: 258-270, 2002
17. Hasty, P., Campisi, J., Hoeljmakers, J., Van Steeg, H., and Vijg, J. Aging and genome maintenance: Lessons from the mouse?: Aging, Science, 299:1355- 1359, 2003.
18. Hogan, In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, and N. Y, 1986.
19. Hyman, R.W., S. Frank, CH. Warden, A. Daluiski, R. Heller, and A.J. Lusis. 1994. Quantitative trait locus analysis of susceptibility to diet-induced atherosclerosis in recombinant inbred mice. Biochem. Genet. 32: 397-407.
20. Kaufman, M. H., and Bard, J. B. L. The Anatomical Basis of Mouse Development. Academic Press, San Diego, CA. 1999.
21. Kellendonk C. et al. MoI 8/0/ 285:175-182, 1999
22. Kessel et al., Science 249:374-379, 1990
23. Kistner, A., et al. PNAS 93:10933-10938, 1996
24. Kuhn R. et al. Science 269: 1427-1429,1995
25. Metzger et al. Eur. J. Neurosci. 15:40-50, 2002
26. Pinkert et al., Genes Dev. 7:268-277, 1987
27. Queen and Baltimore, Ce// 33:741-748, 1983
28. Rossant, J. and Tarn, P. Mouse Development: Patterning, Morphogenesis, and Organogenesis, 2002.
29. Rubera I, et al. J Am Soc Nephrol 15: 2050-2056, 2004
30. Tallini, Y. N., et al. PNAS 103:4753-4758, 2006
31. U.S. Patent No. 4,736,866, filed June 22, 1984
32. U.S. Patent No. 4,870,009 filed December 15, 1983
33. U.S. Patent No. 4,873,191 , filed August 18, 1986
34. U.S. Pat. No. 4,873,316, filed June 23, 1987
35. West, D.B., J. Goudey-Lefevre, B. York, and G. E. Truett. 1994. Dietary obesity linked to genetic loci on chromosomes 9 and 15 in a polygenic mouse model. J. CHn. Invest. 94: 1410-1416.
36. Wimmel et al. Oncogene 9:995-997, 1994
37. Winoto et al., EMBO J. 8:729-733, 1989
38. Yun Bai, et al., American journal of physiology. Renal physiology. 52.F839- F851. 2002
Claims
1. A transgenic mouse comprising: a. a first polynucleotide comprising a genetically encoded sensor (GES) operably linked to an inducible regulatory element; and b. a second polynucleotide encoding a transactivator of the inducible regulatory element operably linked to a tissue-specific regulatory element, wherein expression of the GES may be detected and/or measured optionally in vivo using a non-invasive technique.
2. The transgenic mouse of claim 1 , wherein the GES is a Fluorescence (Forster) resonance energy transfer (FRET)-based sensor or a single fluorescent protein (FP)-based sensor.
3. The transgenic mouse of claim 2, wherein the FRET-based sensor is selected from the group consisting of FIP-CBsm, Cameleon-2, Split Cameleon-2, Cameleon-
3, YC2.0, YC4.0, YC2.1 , YC3.1 , YC2.3, YC2.6, YC3.12, YC3.2, YC3.3, YC3.6, YC6.1 , TN-L15, TN-humTnC, TN-XL, Split indicator of cAMP, CGY-DeM , Cygnet-2, cGES-GKIB, CGES-DE2, cGES-DE5, Raichu-Ras, Raichu-Rap1 , Raichu-Cdc42, Raichu-Rad , Raichu-CRIB, Cdc42-inidicator, Cdc42-GEFs-indicator, Raichu-RhoA, Raichu-RBD, ART, AKAR1 , Srk-indicator, EGFR-indicator, Abl-indicator, Picchu, Aktus, BKAR, CKAR, EAS-2, EAS-3, and EAS-5.
4. The transgenic mouse of claim 2, wherein the single FP-based sensor is selected from the group consisting of Camgaroo-1 , Camgaroo-2, G-CaMP, G- CaMP1.6, G-CaMP2, Cameleon, Troponeon, Flash-Pericam, Split-Pericam, Ratiometric-Pericam, Inverse-Pericam, Case 12, Case 16, Cyan-Sinphos, Green- Sinphos, Yellow-Sinphos, and HyPer.
5. The transgenic mouse of claim 4, wherein the single FP-based sensor is G- CaMP2.
6. The transgenic mouse of claim 5, wherein the G-CaMP2 comprises an N- terminal His tag of from 1-25 His residues.
7. The transgenic mouse of claim 1 , wherein the inducible regulatory element is selected from the group consisting of a tetracycline- or tetracycline derivative- regulated promoter, a steroid-regulated promoter, and a metal-regulated promoter.
8. The transgenic mouse of claim 7, wherein the inducible regulatory element is selected from the group consisting of a tetracycline-responsive promoter, a doxycycline-responsive promoter, a minocycline-responsive promoter, a metallothionine-responsive promoter, an ecdysone-responsive promoter, other steroid-responsive promoters, a rapamycin-responsive promoter, an interferon regulated promoter, a progesterone receptor-derived promoter, and an estrogen receptor derived promoter.
9. The transgenic mouse of claim 1 , wherein the inducible regulatory element is regulated by a tetracycline transactivator.
10. The transgenic mouse of claim 9, wherein the tetracycline transactivator is selected from the group consisting of tTA and rtTA.
11. The transgenic mouse of claim 1 , wherein the tissue-specific regulatory element targets expression of the GES to a tissue selected from the group consisting of neural, epithelial, muscular, connective, brain, skin, intestine, pancreas, kidney, lung, stomach, liver, retinal, esophagus, colon, prostate, ovary, bladder, uterus, and bone.
12. The transgenic mouse of claim 11 , wherein the tissue-specific regulatory element comprises at least one of an olfactory marker protein (OMP) promoter, an enolase promoter, a Kv3.1 potassium channel promoter, a glial fibrillary acidic protein (GFAP) promoter, a brain-specific promoter of the human FGF1 gene, a calcium-calmodulin-dependent kinase Il (CamKII) promoter, a murine Cyp19 gene promoter, a SCN8A promoter, a neuregulin 1 (NRG1) type IV promoter, a rodent beta-adducin promoter, a promoter of exon 1f of aromatase, a promoter of brain- specific angiogenesis inhibitor 1-associated protein, a mouse 14-3-3 eta chain promoter, a CD80 promoter, a rat aldolase C gene promoter, a myelin basic protein promoter, tyrosine hydroxylase promoter, a muscle creatine kinase promoter, portions of the Duchenne muscular dystrophy gene promoter, a promoter of the MyoD gene family, a myocyte-specific enhancer binding factor MEF-2, portions of a human alpha-skeletal actin gene promoter, a tryponin C promoter, an alpha-myosin heavy chain gene promoter, a ventricular alpha-myosin heavy chain gene promoter, a beta-myosin heavy chain gene promoter, a ventricular beta-myosin heavy chain gene promoter, a myosin light chain 2v gene promoter, a ventricular myosin light chain 2 gene promoter, a myosin light chain 2a gene promoter, a ventricular myosin light chain 2 gene promoter, a cardiomyocyte-restricted cardiac ankyrin repeat protein (CARP) gene promoter, a cardiac alpha-actin gene promoter, a cardiac m2 muscarinic acetylcholine gene promoter, an ANP gene promoter, a BNP gene promoter, a cardiac troponin C gene promoter, a cardiac troponin I gene promoter, a cardiac troponin T gene promoter, a cardiac sarcoplasmic reticulum Ca-ATPase gene promoter, a skeletal alpha-actin gene promoter, an artificial cardiac cell-specific promoter, a quail slow myosin chain type 3 (MyHC3) promoter, an ANP promoter, a cGATA-6 enhancer, an iroquois homeobox gene promoter, a K1 promoter, a K5 promoter, a K6 promoter, a K10 promoter, a K14 promoter, an Epstein-Barr virus (EBV) ED-L2 promoter, a major urinary protein (MUP) promoter, an albumin promoter, a transthyretin promoter, an apoE promoter, a phenylalanine hydroxylase promoter, a villin promoter, a fatty acid binding protein promoter (FABP), an intestinal FABP promoter, a cryptdin-2 promoter, a prostate-specific antigen (PSA) promoter, a C(3)1 promoter, an aprostate secretory protein of 94 amino acids (PSP94) promoter, a probasin promoter, an ovarian-specific promoter (OSP-1), an uromodulin promoter, a Tamm-Horsfall protein (THP) promoter, a type 1 gamma-glutamyl transpeptidase promoter, an uroplakin Il promoter, an uroplakin Ia promoter, an uroplakin mi promoter, an urohingin promoter, an uteroglobin promoter, or fragments thereof.
13. The transgenic mouse of claim 12, wherein the tissue-specific regulatory element comprises the OMP promoter.
14. A transgenic mouse comprising: a. a first polynucleotide encoding a fluorescent Ca2+ indicator operably linked to an inducible regulatory element; and b. a second polynucleotide encoding a tetracycline transactivator operably linked to a tissue-specific regulatory element, wherein expression of the fluorescent Ca2+ indicator may be detected and/or measured optionally in vivo using a non-invasive technique.
15. The transgenic mouse of claim 14, wherein the fluorescent Ca2+ indicator is G-CaMP2.
16. The transgenic mouse of claim 14, wherein the inducible regulatory element comprises a tetracycline promoter and the tissue specific regulatory element comprises an olfactory marker protein (OMP) promoter.
17. A method for identifying a candidate compound that modulates intracellular calcium signaling comprising: a. providing a candidate compound; b. providing a transgenic mouse as set forth in claim 14; c. administering the candidate compound to the transgenic mouse; and d. evaluating an effect, if any, of the candidate compound on intracellular calcium signaling.
18. The method of claim 17 wherein the evaluating step is carried out non- invasively through a tissue of the mouse.
19. The method of claim 18, wherein the evaluating step is carried out non- invasively through the skull of the mouse.
20. The method of claim 17, wherein the evaluating step comprises thinning at least a portion of the mouse skull covering an area of interest.
21. The method according to claim 20, wherein the thinning comprises shaving the bone down to about 50 μm thickness.
22. The method of claim 17, wherein the evaluating step is carried out on brain slices.
23. The method according to claim 17, wherein the candidate compound is administered to the mouse through olfaction.
24. The method according to claim 17, wherein the candidate compound is administered directly to a mouse tissue.
25. The method according to claim 17, wherein the candidate compound is administered directly to a brain slice.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/312,094 US9018440B2 (en) | 2006-10-27 | 2007-10-24 | Fluorescent mouse model |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86330106P | 2006-10-27 | 2006-10-27 | |
US60/863,301 | 2006-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008153543A2 true WO2008153543A2 (en) | 2008-12-18 |
WO2008153543A3 WO2008153543A3 (en) | 2009-03-12 |
Family
ID=40130350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/022611 WO2008153543A2 (en) | 2006-10-27 | 2007-10-24 | Fluorescent mouse model |
Country Status (2)
Country | Link |
---|---|
US (1) | US9018440B2 (en) |
WO (1) | WO2008153543A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011024499A (en) * | 2009-07-27 | 2011-02-10 | Nec Soft Ltd | Method for producing nucleic acid, tag nucleic acid for delivery which can organ-specifically deliver delivery object, and use thereof |
EP2496697A2 (en) * | 2009-11-06 | 2012-09-12 | Howard Hughes Medical Institute | Genetically encoded calcium indicators and methods of use |
WO2015057824A1 (en) * | 2013-10-15 | 2015-04-23 | Biogen Idec Ma Inc. | Transgenic animals for in vivo imaging |
CN114461280A (en) * | 2021-12-28 | 2022-05-10 | 浪潮电子信息产业股份有限公司 | BMC double-mirror image flash writing method and related device |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9388427B2 (en) * | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
US9518980B2 (en) | 2012-10-10 | 2016-12-13 | Howard Hughes Medical Institute | Genetically encoded calcium indicators |
DK2842581T3 (en) * | 2013-08-30 | 2019-02-18 | Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin | Bag-like structure with paracrine activity and process for its preparation |
CA3193683A1 (en) | 2020-09-23 | 2022-03-31 | Loren L. Looger | Genetically encoded calcium indicators (gecis) and methods of making and using |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020165364A1 (en) * | 1997-03-14 | 2002-11-07 | Tsien Roger Y. | Fluorescent protein sensors for detection of analytes |
US20050019261A1 (en) * | 2001-11-30 | 2005-01-27 | Hugo Albrecht | Screening method for compounds that modulate neuronal activity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4870009A (en) * | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
JPH09500534A (en) * | 1993-07-22 | 1997-01-21 | メルク エンド カンパニー インコーポレーテッド | Expression of human interleukin-1β in transgenic animals |
-
2007
- 2007-10-24 WO PCT/US2007/022611 patent/WO2008153543A2/en active Application Filing
- 2007-10-24 US US12/312,094 patent/US9018440B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020165364A1 (en) * | 1997-03-14 | 2002-11-07 | Tsien Roger Y. | Fluorescent protein sensors for detection of analytes |
US20050019261A1 (en) * | 2001-11-30 | 2005-01-27 | Hugo Albrecht | Screening method for compounds that modulate neuronal activity |
Non-Patent Citations (4)
Title |
---|
BAIRD ET AL.: 'Circular permutation and receptor insertion within green fluorescent proteins.' PNAS, [Online] vol. 96, September 1999, pages 11241 - 11246 Retrieved from the Internet: <URL:http://www.pnas.org/content/96/20/11241.full.pdf+html> * |
BOZZA ET AL.: 'In vivo imaging of neuronal activity technique by targeted expression of a genetically encoded probe in the mouse.' NEURON vol. 21, 08 April 2004, pages 9 - 21 * |
HASAN ET AL.: 'Functional fluorescent Ca+2 indicator proteins in transgenic mice under TET control.' PLOS BIOLOGY, [Online] vol. 2, no. 6, June 2004, pages 763 - 775 Retrieved from the Internet: <URL:http://biology.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pbio.0020163&ct=1&SESSID=9c8fa77e70171ab13d3b0e0f3a6f71af> * |
TALLINI ET AL.: 'Imaging cellular signals in the heart in vivo : cardiac expression of the high-signal Ca+2 indicator of G-cAMP2' PNAS, [Online] vol. 103, no. 12, 21 March 2006, pages 4753 - 4758 Retrieved from the Internet: <URL:http://www.pnas.org/content/103/12/4753.full.pdf+html> * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011024499A (en) * | 2009-07-27 | 2011-02-10 | Nec Soft Ltd | Method for producing nucleic acid, tag nucleic acid for delivery which can organ-specifically deliver delivery object, and use thereof |
EP2496697A2 (en) * | 2009-11-06 | 2012-09-12 | Howard Hughes Medical Institute | Genetically encoded calcium indicators and methods of use |
EP2496697A4 (en) * | 2009-11-06 | 2013-09-04 | Hughes Howard Med Inst | Genetically encoded calcium indicators and methods of use |
US8629256B2 (en) | 2009-11-06 | 2014-01-14 | Howard Hughes Medical Institute | Genetically encoded calcium indicator polypeptides and nucleic acids encoding same |
WO2015057824A1 (en) * | 2013-10-15 | 2015-04-23 | Biogen Idec Ma Inc. | Transgenic animals for in vivo imaging |
CN114461280A (en) * | 2021-12-28 | 2022-05-10 | 浪潮电子信息产业股份有限公司 | BMC double-mirror image flash writing method and related device |
CN114461280B (en) * | 2021-12-28 | 2024-02-23 | 浪潮电子信息产业股份有限公司 | BMC double-mirror image brushing method and related device |
Also Published As
Publication number | Publication date |
---|---|
WO2008153543A3 (en) | 2009-03-12 |
US20100154068A1 (en) | 2010-06-17 |
US9018440B2 (en) | 2015-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9018440B2 (en) | Fluorescent mouse model | |
US20220256819A1 (en) | Chimeric gene constructs for generation of fluorescent transgenic ornamental fish | |
JP2022125255A (en) | lincRNA-DEFICIENT NON-HUMAN ANIMALS | |
CA2596267A1 (en) | Zebrafish models for alzheimer's disease | |
Tsou et al. | Important roles of ring finger protein 112 in embryonic vascular development and brain functions | |
Chandler et al. | Identification of an ancient Bmp4 mesoderm enhancer located 46 kb from the promoter | |
JP4620456B2 (en) | Transgenic Xenopus embryos and their use as detection agents for environmental endocrine disruptors | |
Meredith | 13 Genetic methods for studying ion channel function in physiology and disease | |
EP1888757A2 (en) | Methods and products for determining f4/80 gene expression in microglial cells | |
JP4851041B2 (en) | Transgenic non-human mammal that monitors changes in intracellular calcium ion concentration | |
Dodd et al. | Transgenic mice expressing luciferase under a 4.5 kb tyrosine hydroxylase promoter | |
Zhang et al. | The regulation of retina specific expression of rhodopsin gene in vertebrates | |
US8357832B2 (en) | F1B-TMIR plasmid vector and transgenic mouse | |
US20060115895A1 (en) | Fish disease models and uses thereof | |
Fink et al. | Non-invasive instant genotyping of fluorescently labeled transgenic mice | |
Kim et al. | The promoter of brain-specific angiogenesis inhibitor 1-associated protein 4 drives developmentally targeted transgene expression mainly in adult cerebral cortex and hippocampus | |
US20050044581A1 (en) | Animals and cells containing a mutated alpha2/omega1 gene | |
WO2002067668A1 (en) | Schizophrenia-like mental disease model animal, method of constructing the same and use thereof | |
Malkovska | Regulation of brain-derived neurotrophic factor in the adult mouse brain | |
ES2338971B1 (en) | ANIMAL MODEL FOR THE STUDY OF LIVING ANGIOGENESIS AND LYMPHANGIOGENESIS. | |
JP2010075065A (en) | Gene-modified animal for evaluating harmfulness of test substance | |
WO2005090561A1 (en) | Method of screening activation inhibitor for macrophage cell | |
Jung | The putative transcription factor Prdm8 is required for the differentiation and maintenance of rod and cone bipolar cells in the mammalian retina | |
Li | Functional analysis of murine homeobox genes | |
Sukumaran | Development of genetically encoded cell type-specific activity markers for the mouse olfactory system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07875098 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07875098 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12312094 Country of ref document: US |